0001104659-21-105299.txt : 20210816 0001104659-21-105299.hdr.sgml : 20210816 20210813185627 ACCESSION NUMBER: 0001104659-21-105299 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210816 DATE AS OF CHANGE: 20210813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Science Strategic Acquisition Corp. Alpha CENTRAL INDEX KEY: 0001830547 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 853594633 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39930 FILM NUMBER: 211173812 BUSINESS ADDRESS: STREET 1: 1447 2ND ST CITY: SANTA MONICA STATE: CA ZIP: 90401 BUSINESS PHONE: 3106214551 MAIL ADDRESS: STREET 1: 1447 2ND ST CITY: SANTA MONICA STATE: CA ZIP: 90401 10-Q 1 ssaau-20210630x10q.htm 10-Q
0001830547--12-312021Q2false0028099027762500776250000.33028099027762500000001830547ssaau:PublicWarrantsMember2021-06-300001830547ssaau:CommonClassaSubjectToRedemptionMember2020-12-310001830547ssaau:CommonClassaSubjectToRedemptionMember2021-06-300001830547ssaau:FounderSharesMemberssaau:SponsorMemberus-gaap:CommonClassBMember2020-10-292020-10-290001830547us-gaap:RetainedEarningsMember2021-06-300001830547us-gaap:AdditionalPaidInCapitalMember2021-06-300001830547us-gaap:RetainedEarningsMember2021-03-310001830547us-gaap:AdditionalPaidInCapitalMember2021-03-3100018305472021-03-310001830547us-gaap:RetainedEarningsMember2020-12-310001830547us-gaap:AdditionalPaidInCapitalMember2020-12-310001830547ssaau:PublicWarrantsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001830547ssaau:PublicAndPrivatePlacementWarrantsMember2021-06-300001830547us-gaap:OverAllotmentOptionMember2021-01-280001830547us-gaap:IPOMember2021-01-280001830547us-gaap:CommonClassBMember2021-03-310001830547ssaau:CommonClassaNotSubjectToRedemptionMember2021-03-310001830547ssaau:PromissoryNoteWithRelatedPartyMember2021-02-022021-02-020001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:PrivatePlacementMember2021-01-282021-01-280001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:PrivatePlacementMember2021-01-012021-06-300001830547us-gaap:RetainedEarningsMember2021-04-012021-06-300001830547us-gaap:RetainedEarningsMember2021-01-012021-03-310001830547us-gaap:FairValueInputsLevel3Member2021-06-300001830547us-gaap:FairValueInputsLevel3Member2021-03-310001830547us-gaap:FairValueInputsLevel3Member2021-01-012021-06-300001830547us-gaap:FairValueInputsLevel3Member2021-01-012021-03-310001830547ssaau:NonRedeemableClassCommonStockAndClassBCommonStockMember2021-04-012021-06-300001830547ssaau:CommonClassaSubjectToRedemptionMember2021-04-012021-06-300001830547ssaau:NonRedeemableClassCommonStockAndClassBCommonStockMember2021-01-012021-06-300001830547ssaau:CommonClassaSubjectToRedemptionMember2021-01-012021-06-300001830547us-gaap:MeasurementInputSharePriceMember2021-06-300001830547us-gaap:MeasurementInputRiskFreeInterestRateMember2021-06-300001830547us-gaap:MeasurementInputPriceVolatilityMember2021-06-300001830547us-gaap:MeasurementInputExpectedTermMember2021-06-300001830547us-gaap:MeasurementInputExercisePriceMember2021-06-300001830547ssaau:MeasurementInputNumberOfTrialsMember2021-06-300001830547us-gaap:MeasurementInputSharePriceMember2021-01-280001830547us-gaap:MeasurementInputRiskFreeInterestRateMember2021-01-280001830547us-gaap:MeasurementInputPriceVolatilityMember2021-01-280001830547us-gaap:MeasurementInputExpectedTermMember2021-01-280001830547us-gaap:MeasurementInputExercisePriceMember2021-01-280001830547ssaau:MeasurementInputNumberOfTrialsMember2021-01-280001830547us-gaap:CommonClassBMember2020-12-310001830547ssaau:CommonClassaNotSubjectToRedemptionMember2020-12-310001830547ssaau:FounderSharesMemberssaau:SponsorMemberus-gaap:CommonClassBMember2021-01-252021-01-250001830547ssaau:PublicWarrantsMemberus-gaap:IPOMember2021-01-280001830547us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-06-300001830547us-gaap:OverAllotmentOptionMember2021-01-282021-01-280001830547us-gaap:IPOMember2021-01-252021-01-250001830547us-gaap:CommonClassAMember2021-01-012021-03-310001830547ssaau:PrivatePlacementWarrantsMember2021-01-012021-03-310001830547ssaau:FounderSharesMemberssaau:SponsorMemberus-gaap:CommonClassBMember2021-01-012021-06-300001830547ssaau:PrivatePlacementWarrantsMember2021-01-012021-06-300001830547ssaau:AdministrativeSupportAgreementMember2021-01-012021-06-300001830547ssaau:PublicWarrantsMemberus-gaap:CommonClassAMember2021-01-012021-06-300001830547us-gaap:IPOMember2021-01-282021-01-280001830547ssaau:PublicWarrantsMemberus-gaap:IPOMember2021-01-282021-01-280001830547ssaau:RelatedPartyLoansMember2021-06-300001830547ssaau:PromissoryNoteWithRelatedPartyMember2020-10-2900018305472021-01-280001830547us-gaap:CommonClassBMember2021-01-012021-06-300001830547us-gaap:CommonClassBMember2021-06-300001830547ssaau:CommonClassaNotSubjectToRedemptionMember2021-06-300001830547ssaau:WorkingCapitalLoansWarrantMemberssaau:RelatedPartyLoansMember2021-06-300001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:PrivatePlacementMember2021-06-300001830547ssaau:PrivatePlacementWarrantsMemberus-gaap:PrivatePlacementMember2021-01-280001830547ssaau:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Memberssaau:PublicWarrantsMember2021-01-012021-06-300001830547ssaau:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Memberssaau:PublicWarrantsMember2021-01-012021-06-300001830547ssaau:PublicWarrantsMember2021-01-012021-06-300001830547us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-3000018305472021-04-012021-06-300001830547us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100018305472021-01-012021-03-310001830547ssaau:CommonClassaNotSubjectToRedemptionMember2021-04-012021-06-300001830547ssaau:CommonClassaNotSubjectToRedemptionMember2021-01-012021-03-310001830547ssaau:FounderSharesMemberssaau:SponsorMemberus-gaap:CommonClassBMember2021-01-2500018305472021-06-3000018305472020-12-310001830547us-gaap:CommonClassAMember2021-01-012021-06-300001830547ssaau:WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceMember2021-01-012021-06-300001830547ssaau:UnitEachConsistingOfOneClassCommonStockAndOneThirdRedeemableWarrantMember2021-01-012021-06-300001830547us-gaap:CommonClassBMember2021-08-100001830547us-gaap:CommonClassAMember2021-08-1000018305472021-01-012021-06-30xbrli:sharesiso4217:USDxbrli:pureiso4217:USDxbrli:sharesssaau:itemssaau:Vote

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2021

      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-39930

Science Strategic Acquisition Corp. Alpha

(Exact name of registrant as specified in its charter)

Delaware

    

85-3594633

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer Identification No.) 

1447 2nd Street

Santa Monica, CA 90401

(Address of principal executive offices including zip code)

Registrant’s telephone number, including area code: (310) 393-3024

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading Symbol(s)

    

Name of each exchange on which registered

Units, each consisting of one share of Class A
common stock, $0.0001 par value, and one-third of
one redeemable warrant

 

SSAAU

 

The Nasdaq Stock Market LLC

Class A common stock

 

SSAA

 

The Nasdaq Stock Market LLC

Redeemable warrants, each whole warrant
exercisable for one share of Class A common stock at
an exercise price of $11.50

 

SSAAW

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes   No 

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes   No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 Large accelerated filer

    

Accelerated filer

 Non-accelerated filer

Smaller reporting company

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No 

As of August 10, 2021, the Registrant had 31,050,000 shares of Class A common stock, par value $0.0001 per share, and 7,762,500 shares of Class B common stock, par value $0.0001 per share, issued and outstanding.

SCIENCE STRATEGIC ACQUISITION CORP. ALPHA

Table of Contents

Page

PART I.     FINANCIAL INFORMATION

Item 1.

Financial Statements

1

Condensed Balance Sheets as of June 30, 2021 (unaudited) and December 31, 2020

1

Condensed Statement of Operations for the three and six months ended June 30, 2021 (unaudited)

2

Condensed Statement of Changes in Stockholders’ Equity for the three and six months ended June 30, 2021 (unaudited)

3

Condensed Statement of Cash Flows for the three and six months ended June 30, 2021 (unaudited)

4

Notes to Interim Condensed Financial Statements (unaudited)

5

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

17

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

19

Item 4.

Controls and Procedures

20

PART II.   OTHER INFORMATION

Item 1.

Legal Proceedings

20

Item 1A.

Risk Factors

20

Item 2.

Use of Proceeds

20

Item 3.

Defaults Upon Senior Securities

21

Item 4.

Mine Safety Disclosures

21

Item 5.

Other Information

21

Item 6.

Exhibits

22

Signatures

23

i

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Science Strategic Acquisition Corp. Alpha

Condensed Balance Sheets

    

June 30, 

December 31, 

2021

2020

(unaudited)

ASSETS

Current assets

Cash

$

868,722

$

20,000

Deferred offering costs

183,912

Prepaid expenses

 

566,520

 

Total Current Assets

1,435,242

203,912

 

 

Marketable securities held in Trust Account

310,534,744

TOTAL ASSETS

$

311,969,986

$

203,912

LIABILITIES AND STOCKHOLDERS' EQUITY

 

  

 

  

Current liabilities

Accrued offering costs

$

135,000

$

151,812

Accrued offering costs - related party

27,100

Accrued expenses

7,018

5,000

Total Current Liabilities

142,018

183,912

Warrant liability

 

13,534,768

 

Deferred underwriting fee payable

 

10,867,500

 

Total Liabilities

 

24,544,286

 

183,912

 

  

 

  

Commitments

 

  

 

  

Class A Common stock subject to possible redemption, 28,240,098 and no shares at redemption value as of June 30, 2021 and December 31, 2020, respectively

282,425,690

 

 

Stockholders' Equity

 

 

Preferred stock, $0.0001 par value; 1,000,000 authorized; none issued and outstanding

 

 

Class A Common stock, $0.0001 par value; 400,000,000 shares authorized; 2,809,902 and no shares issued and outstanding (excluding 28,240,098 and no shares subject to possible redemption) as of June 30, 2021 and December 31, 2020, respectively

 

281

 

Class B Common stock, $0.0001 par value; 40,000,000 shares authorized; 7,762,500 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively

 

776

 

776

Additional paid-in capital

 

7,627,684

 

24,224

Accumulated deficit

 

(2,628,731)

 

(5,000)

Total Stockholders’ Equity

 

5,000,010

 

20,000

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

311,969,986

$

203,912

See accompanying notes to interim condensed financial statements.

1

Science Strategic Acquisition Corp. Alpha

Condensed Statement of Operations

For the three and six months ended June 30, 2021

(Unaudited)

For the

For the

Three Months Ended

Six Months Ended

June 30, 

June 30, 

    

2021

    

2021

Operating costs

    

$

211,844

$

729,474

Loss from operations

(211,844)

(729,474)

Other income (loss):

Unrealized gain on marketable securities held in Trust Account

6,774

34,744

Change in fair value of warrant liability

(3,986,035)

(1,929,002)

Other income (loss), net

(3,979,261)

(1,894,258)

Loss before provision for income taxes

(3,979,261)

(1,894,258)

Provision for income taxes

Net Loss

$

(4,191,105)

$

(2,623,732)

 

 

Weighted average shares outstanding of redeemable Class A common stock

 

28,659,098

28,579,419

Basic and diluted net loss per share, redeemable Class A common stock

$

0.00

$

0.00

 

Weighted average shares outstanding of nonredeemable Class A and Class B common stock

 

10,153,402

 

9,694,261

Basic and diluted net loss per share, nonredeemable Class A and Class B common stock

$

(0.41)

$

(0.27)

See accompanying notes to interim condensed financial statements.

2

Science Strategic Acquisition Corp. Alpha

Condensed Statement of Changes in Stockholders’ Equity

(Unaudited)

Class A

Class B

Additional

Total

Common

Common 

Paid in

Retained

Stockholders’

    

Stock

    

Amount

    

Stock

    

Amount

    

Capital

    

Earnings

    

Equity

Balance — January 1, 2020

$

7,762,500

$

776

$

24,224

$

(5,000)

$

20,000

Sale of 31,050,000 Units, net of underwriting discount and offering expenses

31,050,000

3,105

281,816,326

281,819,431

Sale of 5,473,333 private placement warrants

8,210,000

8,210,000

Common stock subject to possible redemption

(28,462,472)

(2,846)

(284,621,874)

(284,624,720)

Change in value of common stock subject to possible redemption

(196,626)

(20)

(1,992,055)

(1,992,075)

Net income

 

 

 

 

1,567,374

 

1,567,374

Balance — March 31, 2021

 

2,390,902

$

239

7,762,500

$

776

$

3,436,621

$

1,562,374

$

5,000,010

Change in value of common stock subject to possible redemption

419,000

42

4,191,063

4,191,105

Net loss

 

 

 

 

(4,191,105)

 

(4,191,105)

Balance – June 30, 2021

 

2,809,902

$

281

7,762,500

$

776

$

7,627,684

$

(2,628,731)

5,000,010

See accompanying notes to interim condensed financial statements.

3

Science Strategic Acquisition Corp Alpha

Condensed Statement of Cash Flows

For the Six Months Ended June 30, 2021

(Unaudited)

Cash Flows used in Operating Activities:

    

  

Net loss

$

(2,623,732)

Adjustments to reconcile net income to net cash used in operating activities:

 

Unrealized gain on marketable securities held in Trust Account

(34,744)

Change in fair value of warrant liabilities

1,929,002

Changes in operating assets and liabilities:

 

  

Prepaid expenses

(566,520)

Accrued expenses

 

2,018

Net cash used in operating activities

 

(1,293,976)

Cash Flows from Investing Activities:

Investment of cash in Trust Account

(310,500,000)

Net cash used in investing activities

(310,500,000)

 

  

Cash Flows from Financing Activities:

 

  

Proceeds from sale of Units, net of underwriting discounts paid

304,710,744

Proceeds from the sale of Private Placements Warrants

8,210,000

Proceeds from promissory note — related party

 

300,000

Repayment of promissory note — related party

 

(300,000)

Payment of offering costs

 

(278,046)

Net cash provided by financing activities

 

312,642,698

 

  

Net Change in Cash

 

848,722

Cash — Beginning of period

 

20,000

Cash — End of period

$

868,722

 

Supplemental cash flow information:

Cash paid for income taxes

$

Non-Cash investing and financing activities:

 

Change in value of common stock subject to possible redemption

$

(2,199,030)

Initial classification of common stock subject to redemption

$

284,624,720

Initial fair value of warrant liability

$

11,605,766

Deferred offering cost included in accrued offering cost

$

135,000

See accompanying notes to interim condensed financial statements.

4

Science Strategic Acquisition Corp. Alpha

Notes to Interim Condensed Financial Statements

Unaudited

NOTE 1. ORGANIZATION AND PLANS OF BUSINESS OPERATIONS

Organization and General

Science Strategic Acquisition Corp. Alpha (the “Company”) was incorporated in Delaware on October 22, 2020. The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (a “Business Combination”). The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”).

Sponsor and Initial Financing

As of June 30, 2021, the Company had not commenced any operations. All activity through June 30, 2021 relates to the Company’s formation, the initial public offering (the “Initial Public Offering”), which is described below, and identifying a target for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering.

The registration statements for the Initial Public Offering were declared effective on January 25, 2021. On January 28, 2021, the Company consummated the Initial Public Offering of 31,050,000 units (the “Units” and, with respect to the shares of Class A common stock included in the Units sold, the “Public Shares”), which includes the exercise by the underwriter of its over-allotment option in the amount of 4,050,000 Units, at $10.00 per Unit, generating gross proceeds of $310,500,000, which is described in Note 3.

Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 5,473,333 warrants (each, a “Private Placement Warrant” and, collectively, the “Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant in a private placement to SSAC Alpha Sponsor, LLC (the “Sponsor”), generating gross proceeds of $8,210,000, which is described in Note 4.

Transaction costs amounted to $17,495,500, consisting of $6,210,000 of underwriting fees, $10,867,500 of deferred underwriting fees and $418,000 of other offering costs. In addition, cash of approximately $2,300,000 was held outside of the Trust Account (as defined below) and is available for the payment of offering costs and for working capital purposes.

The Trust Account

Following the closing of the Initial Public Offering on January 28, 2021, an amount of $310,500,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the “Trust Account”). The funds in the Trust Account will be invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended. The Company will not be permitted to withdraw any of the principal or interest held in the Trust Account except for the withdrawal of interest to pay taxes, if any. The funds held in the Trust Account will not otherwise be released from the trust account until the earliest of: (1) the Company’s completion of a Business Combination; (2) the redemption of any Public Shares properly submitted in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with a Business Combination or to redeem 100% of the Company’s Public Shares if the Company does not complete a Business Combination on or before January 28, 2023 or (B) with respect to any other provision relating to stockholders’ rights or pre-initial business combination activity; and (3) the redemption of the Company’s Public Shares if the Company has not completed a Business Combination on or before January 28, 2023, subject to applicable law. Based on current interest rates, the Company expects that interest earned on the trust account will be sufficient to pay taxes.

5

Business Combination

The Company’s management has broad discretion with respect to the specific application of the net proceeds from the Initial Public Offering, although substantially all of the net proceeds from the Initial Public Offering are intended to be generally applied toward consummating a Business Combination with (or acquisition of) a Target Business. As used herein, “Target Business” means one or more target businesses that together have an aggregate fair market value equal to at least 80% of the value of the assets held in the Trust Account (excluding taxes payable on the interest earned on the trust account) at the time of the signing of a definitive agreement in connection with a Business Combination. Furthermore, there is no assurance that the Company will be able to successfully effect a Business Combination.

The Company will provide its public stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination, either (i) in connection with a stockholder meeting called to approve such Business Combination or (ii) by means of a tender offer. The public stockholders will be entitled to redeem their shares for a pro rata portion of the amount held in the Trust Account, calculated as of two business days prior to the completion of a Business Combination, including any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. The per-share amount to be distributed to the public stockholders who redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter (as discussed in Note 6). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants. As a result, shares of common stock are recorded at their redemption amount and classified as temporary equity, in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, “Distinguishing Liabilities from Equity” (“ASC 480”).

The decision as to whether the Company will seek stockholder approval of a Business Combination or will allow stockholders to sell their shares in a tender offer will be made by the Company, in its sole discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would otherwise require the Company to seek stockholder approval unless a vote is required by law or stock exchange listing requirements. If the Company seeks stockholder approval, it will complete its Business Combination only if a majority of the shares of common stock voted are voted in favor of a Business Combination. However, in no event will the Company redeem its Public Shares in an amount that would cause its net tangible assets to be less than $5,000,001 upon consummation of a Business Combination. In such case, the Company would not proceed with the redemption of its Public Shares and the related Business Combination, and instead may search for an alternate Business Combination.

The Company will have until January 28, 2023 to complete its initial Business Combination. If the Company does not complete a Business Combination by such date (or such longer period as provided in an amendment to the Company’s amended and restated certificate of incorporation approved by its stockholders (an “Extension Period”)), it shall (i) cease all operations except for the purposes of winding up; (ii) as promptly as reasonably possible but not more than 10 business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $100,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and its board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete its initial Business Combination by January 28, 2023 or during any Extension Period. The initial stockholders have entered into a letter agreement with the Company, pursuant to which they have waived their rights to liquidating distributions from the Trust Account with respect to their Founder Shares (as defined in Note 5) if the Company fails to complete its initial Business Combination by January 28, 2023 or during any Extension Period. However, if the initial stockholders acquire Public Shares, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete its initial Business Combination by January 28, 2023 or during any Extension Period.

The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company’s independent auditors) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.00 per Public Share or (2) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, due to reductions in value of the trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriter of the Initial Public Offering against certain liabilities, including liabilities

6

under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third party, then the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to have all third parties, including, but not limited to, all vendors, service providers (other than its independent registered public accounting firm), prospective target businesses and other entities with which the Company does business execute agreements with the Company waiving any right, title, interest or claims of any kind in or to any monies held in the Trust Account.

Liquidity and Capital Resources

As of June 30, 2021, the Company had $868,722 cash held outside of the Trust Account and working capital of $1,293,227.

The Company’s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through the payment of $25,000 from the Sponsor to cover certain offering costs on the Company’s behalf in exchange for the issuance of Founder Shares (as discussed in Note 5), and a loan from the Sponsor of $300,000 under the Promissory Note (as discussed in Note 5). The Company repaid the Promissory Note in full on February 2, 2021. Subsequent to the consummation of the Initial Public Offering, the Company’s liquidity has been satisfied through the net proceeds from the consummation of the Initial Public Offering and the private placement held outside of the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (as discussed in Note 5). As of June 30, 2021, there were no working capital loans outstanding.

Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of a Business Combination or one year from the date the financial statements are issued. Over this time period, the Company will use these funds to pay existing accounts payable, identify and evaluate prospective initial Business Combination candidates, perform due diligence on prospective target businesses, pay for travel expenditures, select a target business to merge with or acquire, and structure, negotiate and consummate the Business Combination.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on April 7, 2021, which contains the audited financial statements and notes thereto. The financial information as of December 31, 2020 is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The interim results for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

7

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is either not an emerging growth company or an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates

The preparation of the condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. Cash equivalents consist of mutual funds. The Company did not have any cash equivalents as of June 30, 2021 and December 31, 2020.

Offering Costs

Offering costs consist of legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial Public Offering. These costs, together with the upfront underwriting discounts, the deferred underwriting commissions and the financial advisory fee in connection with the Initial Public Offering were charged to stockholders’ equity and warrants exercisable for Class A common stock upon the completion of the Initial Public Offering. Approximately $17.1 million of the offering costs were related to the issuance of Class A common stock and charged to stockholders’ equity and approximately $0.4 million of the offering costs were related to the warrant liabilities and charged to the condensed statement of operations.

Marketable Securities Held in Trust Account

At June 30, 2021, substantially all of the assets held in the Trust Account were held in money market funds which invest in United States Treasury securities.Through June 30, 2021, the Company has not withdrawn any monies from the Trust Account.

Class A Common Stock Subject to Possible Redemption

The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC 480. Shares of Class A common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s Class A common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at June 30, 2021, Class A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet.

8

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2021 and December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception.

On March 27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) into law. The CARES Act includes several significant business tax provisions that, among other things, would eliminate the taxable income limit for certain net operating losses (“NOL”) and allow businesses to carry back NOLs arising in 2018, 2019 and 2020 to the five prior years, suspend the excess business loss rules, accelerate refunds of previously generated corporate alternative minimum tax credits, generally loosen the business interest limitation under section 163(j) of the Internal Revenue Code of 1986, as amended, from 30 percent to 50 percent among other technical corrections included in the Tax Cuts and Jobs Act tax provisions. The Company does not believe that the CARES Act will have a significant impact on Company's financial position or statement of operations.

Net Loss per Share

Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Shares of common stock subject to possible redemption at June 30, 2021, which are not currently redeemable and are not redeemable at fair value, have been excluded from the calculation of basic net loss per common share since such shares, if redeemed, only participate in their pro rata share of the Trust Account earnings. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the private placement to purchase an aggregate of 15,823,333 shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. As a result, diluted net loss per common share is the same as basic net loss per common share for the periods presented.

The Company’s statement of operations includes a presentation of net earnings (loss) per share for common shares subject to possible redemption and applies the two-class method in calculating net earnings (loss) per share. Net earnings per common share, basic and diluted, for Class A redeemable common stock is calculated by dividing the allocable interest income earned on the Trust Account, net of applicable franchise and income taxes, by the weighted average number of Class A common stock subject to possible redemption outstanding since original issuance. Net loss per share, basic and diluted, for Class A and Class B non-redeemable common stock is calculated by dividing the net loss, adjusted for income attributable to Class A redeemable common stock, by the weighted average number of Class A and Class B non-redeemable common stock outstanding for the period. Class B non-redeemable common stock includes the Founder Shares as these shares do not have any redemption features and do not participate in the income earned on the Trust Account.

9

The following table reflects the calculation of basic and diluted net earnings (loss) per common share (in dollars, except per share amounts):

    

    

Six Months 

Three Months Ended

Ended 

June 30, 

June 30, 

2021

2021

Class A Common Stock subject to possible redemption

Numerator: Earnings attributable to Class A Common Stock subject to possible redemption

Unrealized gain on marketable securities held in Trust Account

$

4,929

$

25,280

Net earnings attributable to Class A Common Stock subject to possible redemption

$

4,929

$

25,280

Denominator: Weighted average Class A Common Stock subject to possible redemption

Basic and diluted weighted average shares outstanding, Class A Common Stock subject to possible redemption

28,659,098

28,579,419

Basic and diluted net earnings per share, Class A Common Stock subject to possible redemption

$

0.00

$

0.00

Non-Redeemable Class A and Class B Common Stock

Numerator: Net loss minus net earnings

Net loss

$

(4,191,105)

$

(2,623,732)

Less: Net earnings attributable to Class A Common Stock subject to possible redemption

 

(4,929)

 

(25,280)

Non-redeemable net loss

$

(4,196,034)

(2,649,012)

Denominator: Weighted average Non-Redeemable Class A and Class B Common Stock

Basic and diluted weighted average shares outstanding, Non-Redeemable Class A and Class B Common Stock

10,153,402

9,694,261

Basic and diluted net loss per share, Non-Redeemable Class A and Class B Common Stock

$

(0.41)

(0.27)

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.

Fair Value of Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurement” (“ASC 820”), approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature.

Warrants Exercisable for Class A Common Stock

The Company accounted for the 15,823,333 warrants issued in connection with the Initial Public Offering and the Private Placement Warrants (collectively, the “Warrants”) as either equity-classified or liability-classified instruments based on an assessment of the Warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the company’s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s condensed financial statements.

10

NOTE 3. INITIAL PUBLIC OFFERING

On January 28, 2021, pursuant to the Initial Public Offering, the Company sold 31,050,000 Units, which includes the full exercise by the underwriter of its over-allotment option in the amount of 4,050,000 Units, at a price of $10.00 per Unit. Each Unit consists of one share of Class A common stock and one-third of one (each whole warrant, a “Public Warrant”). Each whole Public Warrant entitles the holder to purchase one share of Class A common stock at an exercise price of $11.50 per share, subject to adjustment (see Note 8).

NOTE 4. PRIVATE PLACEMENT

Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 5,473,333 Private Placement Warrants, at a price of $1.50 per Private Placement Warrant, for an aggregate purchase price of $8,210,000 in a private placement. Each Private Placement Warrant is exercisable to purchase one share of Class A common stock at an exercise price of $11.50 per share. $6,210,000 of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination by January 28, 2023 or during any Extension Period, the proceeds of the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Placement Warrants.

NOTE 5. RELATED PARTY TRANSACTIONS

Founder Shares

On October 29, 2020, the Sponsor purchased 6,468,750 Founder Shares (as defined below) for an aggregate purchase price of $25,000. On January 25, 2021, the Company effected a stock dividend of 1,293,750 shares of Class B common stock to holders of Class B common stock on a pro rata basis based on their holdings, resulting in the Company’s initial stockholders holding an aggregate of 7,762,500 Founder Shares.

The initial stockholders have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Class B common stock or Class A common stock received upon conversion thereof (together, “Founder Shares”) until the earlier of: (A) one year after the completion of a Business Combination; and (B) subsequent to a Business Combination (x) if the last reported sale price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, rights issuances, consolidations, reorganizations, recapitalizations and other similar transactions) for any 20 trading days within any 30-trading day period commencing at least 150 days after a Business Combination or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the Company’s public stockholders having the right to exchange their shares of common stock for cash, securities or other property.

Promissory Note — Related Party

On October 29, 2020, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the “Promissory Note”). The Promissory Note was non-interest bearing and payable on the earlier of December 31, 2021 or the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $300,000 remained outstanding at the closing of the Initial Public Offering on January 28, 2021. On February 2, 2021, the Company repaid the Promissory Note in full.

Administrative Services Agreement

The Company agreed, commencing on January 26, 2021 through the earlier of the Company’s consummation of a Business Combination and its liquidation, to pay an affiliate of the Sponsor a total of $10,000 per month for office space, administrative and support services.

Related Party Loans

In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working

11

Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender's discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $1.50 per warrant. Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans.

NOTE 6. COMMITMENTS

Registration Rights

The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued on conversion of Working Capital Loans (and any Class A common stock issuable upon the exercise of the Private Placement Warrants or warrants issued upon conversion of the Working Capital Loans and upon conversion of the Founder Shares) will be entitled to registration rights pursuant to a registration rights agreement to be signed prior to or on the effective date of the Initial Public Offering requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to the Company’s Class A common stock). The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until termination of the applicable lock-up period. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The underwriters are entitled to a deferred fee of $0.35 per Unit, or $10,867,500 in the aggregate. The deferred fee will be waived by the underwriters in the event that the Company does not complete a Business Combination, subject to the terms of the underwriting agreement by January 28, 2023.

NOTE 7. STOCKHOLDERS’ EQUITY

Preferred Stock — The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share. The Company’s board of directors is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. The board of directors is able to, without stockholder approval, issue shares of preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of the common stock and could have anti-takeover effects. At June 30, 2021, there were no shares of preferred stock issued or outstanding.

Common Stock

Class A Common Stock — The Company is authorized to issue 400,000,000 shares of Class A common stock with a par value of $0.0001 per share. Holders of Class A common stock are entitled to one vote for each share. At June 30, 2021, there were 2,809,902 shares of Class A common stock issued and outstanding, excluding 28,240,098 shares of Class A common stock subject to possible redemption.

Class B Common Stock —The Company is authorized to issue 40,000,000 shares of Class B common stock with a par value of $0.0001 per share. Holders of Class B common stock are entitled to one vote for each share. At June 30, 2021, there were 7,762,500 shares of Class B common stock issued and outstanding.

Holders of Class B common stock have the right to elect all of the Company’s directors prior to a Business Combination. Holders of Class A common stock and Class B common stock will vote together as a single class on all other matters submitted to a vote of stockholders except as required by law.

The Class B common stock will automatically convert into Class A common stock at the time of the completion of a Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts issued in the Initial Public

12

Offering and related to the closing of a Business Combination, the ratio at which Founder Shares will convert into Class A common stock will be adjusted (subject to waiver by holders of a majority of the Class B common stock) so that the number of shares of Class A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of the common stock issued and outstanding upon completion of the Initial Public Offering plus the number of shares of Class A common stock and equity-linked securities issued or deemed issued in connection with a Business Combination, excluding any shares of Class A common stock or equity-linked securities issued, or to be issued, to any seller in a Business Combination.

NOTE 8. WARRANTS

Warrants — Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants and only whole warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months after the closing of the Initial Public Offering. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.

If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement governing the Warrants (the “Warrant Agreement”). The exercise price and number of shares of Class A common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However except as described below, the warrants will not be adjusted for issuances of Class A common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of the warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution form the Company’s assets held outside the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.

In addition, if (x) the Company issues additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of the Company’s initial Business Combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by our board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any founder shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Company’s initial Business Combination on the date of the completion of the Company’s initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of shares of the Company’s Class A common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummate a Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described below under “Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $18.00” and “Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described below under “Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price.

The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the Public Warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration or a valid exemption from registration is available. No Public Warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their Public Warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption from registration is available.

The Company has agreed that as soon as practicable, but in no event later than 15 business days, after the closing of a Business Combination, it will use its commercially reasonable efforts to file with the SEC a registration statement registering the issuance, under the Securities Act, of the Class A common stock issuable upon exercise of the Public Warrants. The Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of a Business Combination and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the Public Warrants in accordance with the provisions of the Warrant Agreement. Notwithstanding the above, if the Class A common stock is, at

13

the time of any exercise of a Public Warrant, not listed on a national securities exchange such that they do not satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their Public Warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.

Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $18.00. Once the Public Warrants become exercisable, the Company may redeem the Public Warrants:

in whole and not in part;
at a price of $0.01 per Public Warrant;
upon not less than 30 days' prior written notice of redemption to each warrant holder; and
if, and only if, the last reported sale price of shares of the Class A common stock for any 20 trading days within a 30 -trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the “Reference Value”) equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant).

Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $10.00. Once the Public Warrants become exercisable, the Company may redeem the Public Warrants:

in whole and not in part;
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the “fair market value” of the Class A common stock;
if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted); and
if the Reference Value is less than $18.00 per share (as adjusted), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants.

If and when the Public Warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.

The Private Placement Warrants are identical to the Public Warrants underlying the Units that were sold in the Initial Public Offering, except that the Private Placement Warrants and the Class A common stock issuable upon the exercise of the Private Placement Warrants are not transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants are exercisable on a cashless basis and are non-redeemable, except as described above, so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants are redeemable by the Company and are exercisable by such holders on the same basis as the Public Warrants.

The Warrants are not considered to be indexed to the Company’s stock price. In accordance with FASB ASC 815, the warrants were classified as a liability in the total amount of $11.6 million at January 28, 2021. In addition, the warrants must be valued every reporting period and adjusted to market with the increase or decrease being adjusted through earnings. As of June 30, 2021 the fair value of the warrant liability was $13.5 million.

NOTE 9. FAIR VALUE MEASUREMENTS

The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually.

14

The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:

Level 1:Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.

Level 1 assets and liabilities at fair value is comprised of Cash, Cash held in the Trust Account and Public Warrants. The company has no other Level 1 assets or liabilities at fair value and no Level 2 assets or liabilities at fair value at June 30, 2021 and December 31, 2020. The Company has warrants exercisable for Class A common stock with a fair value of $13,534,768 and $0 as of June 30, 2021 and December 31, 2020, respectively. The Private Placement Warrants are classified as Level 3 based on a valuation model that utilizes both observable and unobservable inputs. Observable inputs include market prices of warrants issued by other special purpose acquisition companies and unobservable inputs include model adjustments for valuation uncertainty pertaining to the probability of the Company consummating a Business Combination. There were no transfers into or out of Level 3 within the fair value hierarchy during the three and six month periods ended June 30, 2021. The following table provides a summary of the changes in fair value of the Company’s Level 3 assets and liabilities for the six months ended June 30, 2021.

Private Placement Warrants

Exercisable for

Class A common

    

stock

Balance December 31, 2020

$

Initial fair value

 

4,050,266

Changes in fair value of warrant liability

(711,533)

Fair Value at March 31, 2021

3,338,733

Change in fair value of warrant liability

 

1,342,979

Fair Value at June 30, 2021

$

4,681,712

The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at June 30, 2021 and December 31, 2020, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

    

    

June 30, 

    

December 31, 

Description

Level

 

2021

 

2020

Assets:

 

  

 

  

 

  

Marketable securities held in Trust Account

 

1

$

310,534,744

$

Liabilities:

 

  

 

 

  

Public warrants

1

$

8,853,056

$

Private warrants

3

$

4,681,712

$

The Warrants were initially valued using a Monte Carlo simulation model, with the observable assumptions as provided in the table below. Significant increases in the expected stock prices and expected liquidity would result in a significantly higher fair value measurement. Significant increases in either the probability or severity of default of the host instrument would result in a significantly lower fair value measurement. The measurement of the Public Warrants after the detachment of the Public Warrants from the Units is classified as Level 1 due to the use of an observable market quote in an active market. For periods subsequent to the detachment of the

15

Public Warrants from the Units, the closing price of the Public Warrant was used as the fair value for the Public Warrants as of each relevant date.

    

As of 

    

As of 

 

January 28,

June 30,

 

2021

2021

 

Stock price on valuation date

$

9.76

$

9.71

Exercise price

$

11.50

$

11.50

Term (years)

 

5.93

 

6.09

Expected volatility

 

14.0

%

 

13.3

%

Weighted average risk-free interest rate

 

0.57

%

 

1.05

%

Trials

 

400

 

400

NOTE 10. SUBSEQUENT EVENTS

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements.

16

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

References in this quarterly report on Form 10-Q (the “Quarterly Report”) to “we,” “our,” “us,” and “Company” refer to Science Strategic Acquisition Corp. Alpha. References to our “management” or our “management team” refer to our officers and directors, and references to our “Sponsor” refer to SSAC Alpha Sponsor, LLC. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Special Note Regarding Forward-Looking Statements

This Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are not historical facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Quarterly Report including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations thereof and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission (the “SEC”) on April 7, 2021, and the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, which was filed with the SEC on May 28, 2021. Except as expressly required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Overview

We are a blank check company incorporated as a Delaware corporation on October 22, 2020 for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, which we refer to as a Business Combination. We completed our initial public offering (our “IPO”) on January 28, 2021, which is described below under “—Liquidity and Capital Resources.”

While we may pursue a business combination target in any industry, we currently intend to focus our search for a target business in the direct-to-consumer brands, direct-to-consumer-services and mobile and social entertainment sectors. Since completing our IPO, we have reviewed, and continue to review, a number of opportunities to enter into a Business Combination with an operating business, but we are not able to determine at this time whether we will complete a Business Combination with any of the target businesses that we have reviewed or with any other target business. We intend to effectuate a Business Combination using cash from the proceeds of our IPO and the sale of the Private Placement Warrants (as defined below), our capital stock, debt, or a combination of cash, stock and debt.

Results of Operations

For the three and six months ended June 30, 2021, we had a net loss of $4.2 million and $2.6 million, respectively. Our business activities during the three and six months ended June 30, 2021 consisted primarily of organizational activities and those necessary to prepare for and complete our IPO and, subsequent to our IPO, identifying and evaluating prospective acquisition candidates for a Business Combination. We believe that we have sufficient funds available to complete our efforts to effect a Business Combination with an operating business by January 28, 2023. However, if our estimates of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to our Business Combination.

We do not expect to generate any operating revenues until after the completion of our Business Combination. We generate non-operating income in the form of interest income on marketable securities held in the Trust Account (as defined below). We incur

17

expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence and other expenses in connection with searching for a target and completing a Business Combination.

Liquidity and Capital Resources

As of June 30, 2021, we had approximately $0.9 million in our operating bank account, and working capital of approximately $1.3 million.

Our liquidity needs up to the completion of our IPO on January 28, 2021 had been satisfied through a payment from our Sponsor of $25,000 for 7,762,500 shares (the “Founder Shares”) of our Class B common stock and a loan of $300,000 from our Sponsor, which was repaid on February 2, 2021.

On January 28, 2021, we consummated our IPO of 31,050,000 units (the “Units”), including the issuance of 4,050,000 Units as a result of the underwriter’s full exercise of its over-allotment option. Each Unit consists of one share of our Class A common stock and one-third of one warrant of the Company, with each whole warrant entitling the holder thereof to purchase one whole share of Class A common stock at a price of $11.50 per share, subject to certain adjustments. The Units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $310,500,000. Simultaneously with the closing of our IPO, we completed the private sale of an aggregate of 5,473,333 private placement warrants (the “Private Placement Warrants”) to our Sponsor at a purchase price of $1.50 per private placement warrant, generating gross proceeds to us of $8,210,000.

A total of $310,500,000, comprised of the net proceeds of the IPO and the sale of the Private Placement Warrants, was placed in a U.S.-based trust account (the “Trust Account”) at JP Morgan Chase Bank, N.A., maintained by Continental Stock Transfer & Trust Company, acting as trustee. Transaction costs for the IPO and the sale of the Private Placement Warrants amounted to $17,495,500 consisting of $6,210,000 of underwriting fees, $10,867,500 of deferred underwriting fees and $418,000 of other offering costs. In addition, as of June 30, 2021, approximately $0.9 million of cash was held outside of the Trust Account and is available for working capital purposes.

As of June 30, 2021, we had marketable securities held in the Trust Account of $310,534,744 (including approximately $34,744 of interest income and unrealized gain) consisting of U.S. Treasury Bills with a maturity of 180 days or less. Interest income on the balance in the Trust Account may be used by us to pay taxes.

For the six months June 30, 2021, cash used in operating activities was $1,293,976. Net loss of $2,623,732 was affected by a loss on the change in fair value of our warrant liability of $1,929,002 and interest on marketable securities held in the trust account of $34,744. Changes in operating assets and liabilities used $564,503 of cash for operating activities.

We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account, which interest shall be net of taxes payable and excluding deferred underwriting commissions, to complete our Business Combination. We may make permitted withdrawals from the Trust Account to pay our taxes, including franchise taxes and income taxes. To the extent that our capital stock or debt is used, in whole or in part, as consideration to complete our Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

We intend to use funds held outside the Trust Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements of prospective target businesses, structure, negotiate and complete a business combination, and to pay taxes to the extent the interest earned on the Trust Account is not sufficient to pay our taxes.

In order to fund working capital deficiencies or finance transaction costs in connection with an intended Business Combination, our Sponsor or an affiliate of our Sponsor or certain of our directors and officers may, but are not obligated to, loan us funds as may be required. If we complete our Business Combination, we may repay such loaned amounts out of the proceeds of the Trust Account released to us. Otherwise, such loans may be repaid only out of funds held outside the Trust Account. In the event that our Business Combination does not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from our Trust Account would be used to repay such loaned amounts. Up to $1,500,000 of such loans may be convertible

18

into warrants at a price of $1.50 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants issued to our Sponsor. As of June 30, 2021, there were no amounts outstanding under any such working capital loans.

Management believes that the Company will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of a Business Combination or at least through August 31, 2022. However, we may need to raise additional funds in order to meet the expenditures required for operating our business. If our estimates of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to our Business Combination. Moreover, we may need to obtain additional financing either to complete our Business Combination or because we become obligated to redeem a significant number of our public shares upon completion of our Business Combination, in which case we may issue additional securities or incur debt in connection with such Business Combination.

Off-Balance Sheet Financing Arrangements

We have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of June 30, 2021. We do not participate in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

Contractual Obligations

We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than as described below.

We have an agreement to pay an affiliate of our Sponsor a monthly fee of $10,000 for office space and administrative and support services provided to the Company. We began incurring these fees on February 1, 2021 and will continue to incur these fees monthly until the earlier of the completion of a Business Combination and the Company’s liquidation.

The underwriter of the IPO is entitled to a deferred discount of $0.35 per Unit, or $10,867,500 in the aggregate. The deferred discount will become payable to the underwriter from the amounts held in the Trust Account solely in the event that we complete a Business Combination, subject to the terms of the underwriting agreement.

Critical Accounting Policies

The preparation of condensed financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have not identified any critical accounting policies.

Recent Accounting Standards

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our condensed financial statements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are a smaller reporting company as defined by Rule 12b-2 under the Exchange Act and are not required to provide the information otherwise required under this item.

19

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of our management, including our principal executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the fiscal quarter ended June 30, 2021, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, and in light of the material weaknesses in internal controls described below, our Chief Executive Officer and Chief Financial Officer have concluded that during the period covered by this report, our disclosure controls and procedures were not effective.

Our internal control over financial reporting did not result in the proper accounting classification of certain of the warrants we issued in January 2021 which, due to its impact on our financial statements, we determined to be a material weakness. This mistake in classification was brought to our attention only when the SEC issued a Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”) dated April 12, 2021 (the “SEC Statement”). The SEC Statement addresses certain accounting and reporting considerations related to warrants of a kind similar to those we issued at the time of our IPO in January 2021. In addition, the Company did not properly account for the classification of offering costs attributed to the January 2021 offering, which we also determined to be a material weakness.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the quarter ended June 30, 2021 covered by this Quarterly Report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, with the exception of the below.

The Chief Executive Officer and Chief Financial Officer performed additional accounting and financial analyses and other post-closing procedures including consulting with subject matter experts related to the accounting for the public warrants and Private Placement Warrants. The Company’s management has expended, and will continue to expend, a substantial amount of effort and resources for the remediation and improvement of our internal control over financial reporting. While we have processes to properly identify and evaluate the appropriate accounting technical pronouncements and other literature for all significant or unusual transactions, we have expanded and will continue to improve these processes to ensure that the nuances of such transactions are effectively evaluated in the context of the increasingly complex accounting standards.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may be involved in various claims and legal actions in the ordinary course of business. We are not currently involved in any material legal proceedings outside the ordinary course of our business.

Item 1A. Risk Factors

There have been no material changes from the risk factors disclosed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2020 and in our Quarterly Report on Form 10-Q for the period ended March 31,2021.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Use of Proceeds

On January 28, 2021, we consummated our IPO of 31,050,000 Units, including the issuance of 4,050,000 Units as a result of the underwriter’s full exercise of its over-allotment option. Each Unit consists of one share of our Class A common stock and one-third of

20

one warrant of the Company, with each whole warrant entitling the holder thereof to purchase one whole share of our Class A common stock at a price of $11.50 per share, subject to certain adjustments. The Units were sold at a price of $10.00 per unit, generating aggregate gross proceeds to the Company of $310,500,000. Credit Suisse Securities (USA) LLC acted as a sole underwriter of our IPO. The securities sold in our IPO were registered under the Securities Act on registration statements on Form S-1 (File Nos. 333-251987 and 333-252416). The registration statements became effective on January 25, 2021.

Following our IPO and the sale of the Private Placement Warrants, a total of $310,500,000 of the net proceeds from the sale of the Units and Private Placement Warrants was deposited in the Trust Account. Transaction costs amounted to $17,495,500, consisting of $6,210,000 of underwriting discounts and commissions, $10,867,500 of deferred underwriting discounts commissions and $418,000 of other cash offering costs. In addition, as of June 30, 2021, $0.9 million of cash was held outside of the Trust Account and is available for working capital purposes.

For a description of the use of the net proceeds from our IPO, see Part I, Item 2 of this Quarterly Report.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

21

Item 6. Exhibits

Exhibit

Number

    

Description

3.1

Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on January 29, 2021).

3.2

Bylaws (incorporated by reference to Exhibit 3.3 filed with the Form S-1 filed by the Registrant on January 8, 2021).

4.1

Specimen Unit Certificate (incorporated by reference to Exhibit 4.1 filed with the Form S-1/A filed by the Registrant on January 20, 2021).

4.2

Specimen Share of Class A common stock Certificate (incorporated by reference to Exhibit 4.2 filed with the Form S-1/A filed by the Registrant on January 20, 2021).

4.3

Specimen Warrant Certificate (included in Exhibit 4.4) (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on January 29, 2021).

4.4

Warrant Agreement, dated January 25, 2021, between the Company and Continental Stock Transfer & Trust Company, as warrant agent (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on January 29, 2021).

31.1*

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1**

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted

pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2**

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101*

The following financial information from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) Condensed Balance Sheets; (ii) Condensed Statement of Operations; (iii) Condensed Statement of Changes in Stockholders’ Equity; (iv) Condensed Statement of Cash Flows; and (v) Notes to Condensed Financial Statements.

104*

Cover Page Interactive Data File (embedded within the Inline XBRL document)

*Filed herewith

**Furnished herewith

22

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Science Strategic Acquisition Corp. Alpha

Date: August 13, 2021

By:

/s/ Michael Jones

Mr. Michael Jones

Chief Executive Officer

(principal executive officer)

Date: August 13, 2021

By:

/s/ Thomas Dare

Mr. Thomas Dare

Chief Financial Officer

(principal financial and accounting officer)

23

EX-31.1 2 ssaau-20210630xex31d1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael Jones, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Science Strategic Acquisition Corp. ALPHA;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)[Omitted];

(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 13, 2021

By:

/s/ Michael Jones

Michael Jones

Chief Executive Officer

(Principal Executive Officer)


EX-31.2 3 ssaau-20210630xex31d2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Thomas Dare, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Science Strategic Acquisition Corp. ALPHA;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)[Omitted];

(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 13, 2021

By:

/s/ Thomas Dare

Thomas Dare

Chief Accounting Officer

(Principal Financial and Accounting Officer)


EX-32.1 4 ssaau-20210630xex32d1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Science Strategic Acquisition Corp. ALPHA (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, in the capacity and on the date indicated below, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)     The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 13, 2021

By:

/s/ Michael Jones

Michael Jones

Chief Executive Officer

(Principal Executive Officer)


EX-32.2 5 ssaau-20210630xex32d2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Science Strategic Acquisition Corp. ALPHA (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, in the capacity and on the date indicated below, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)     The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 13, 2021

By:

/s/ Thomas Dare

Thomas Dare

Chief Financial Officer

(Principal Financial and Accounting Officer)


EX-101.SCH 6 ssaau-20210630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Statement of Operations link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - ORGANIZATION AND PLANS OF BUSINESS OPERATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Net Income per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00205 - Statement - Condensed Statement of Operations (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Statement of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00305 - Statement - Condensed Statement of Changes in Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - PRIVATE PLACEMENT link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restatement of Previously Issued Financial Statement as of January 28, 2021 (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - INITIAL PUBLIC OFFERING (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - PRIVATE PLACEMENT (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - RELATED PARTY TRANSACTIONS - Founder Shares (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - RELATED PARTY TRANSACTIONS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - COMMITMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock Shares (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock Shares (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - FAIR VALUE MEASUREMENTS - Level 3 Fair Value Measurements Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - FAIR VALUE MEASUREMENTS - Change in the Fair Value of the Warrant Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - ORGANIZATION AND PLANS OF BUSINESS OPERATIONS link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - INITIAL PUBLIC OFFERING link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - COMMITMENTS link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - WARRANTS link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 ssaau-20210630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 ssaau-20210630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 ssaau-20210630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 ssaau-20210630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 ssaau-20210630x10q_htm.xml IDEA: XBRL DOCUMENT 0001830547 ssaau:PublicWarrantsMember 2021-06-30 0001830547 ssaau:CommonClassaSubjectToRedemptionMember 2020-12-31 0001830547 ssaau:CommonClassaSubjectToRedemptionMember 2021-06-30 0001830547 ssaau:FounderSharesMember ssaau:SponsorMember us-gaap:CommonClassBMember 2020-10-29 2020-10-29 0001830547 us-gaap:RetainedEarningsMember 2021-06-30 0001830547 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001830547 us-gaap:RetainedEarningsMember 2021-03-31 0001830547 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001830547 2021-03-31 0001830547 us-gaap:RetainedEarningsMember 2020-12-31 0001830547 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001830547 ssaau:PublicWarrantsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001830547 ssaau:PublicAndPrivatePlacementWarrantsMember 2021-06-30 0001830547 us-gaap:OverAllotmentOptionMember 2021-01-28 0001830547 us-gaap:IPOMember 2021-01-28 0001830547 us-gaap:CommonClassBMember 2021-03-31 0001830547 ssaau:CommonClassaNotSubjectToRedemptionMember 2021-03-31 0001830547 ssaau:PromissoryNoteWithRelatedPartyMember 2021-02-02 2021-02-02 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2021-01-28 2021-01-28 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2021-01-01 2021-06-30 0001830547 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001830547 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001830547 us-gaap:FairValueInputsLevel3Member 2021-06-30 0001830547 us-gaap:FairValueInputsLevel3Member 2021-03-31 0001830547 us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-06-30 0001830547 us-gaap:FairValueInputsLevel3Member 2021-01-01 2021-03-31 0001830547 ssaau:NonRedeemableClassCommonStockAndClassBCommonStockMember 2021-04-01 2021-06-30 0001830547 ssaau:CommonClassaSubjectToRedemptionMember 2021-04-01 2021-06-30 0001830547 ssaau:NonRedeemableClassCommonStockAndClassBCommonStockMember 2021-01-01 2021-06-30 0001830547 ssaau:CommonClassaSubjectToRedemptionMember 2021-01-01 2021-06-30 0001830547 us-gaap:MeasurementInputSharePriceMember 2021-06-30 0001830547 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-06-30 0001830547 us-gaap:MeasurementInputPriceVolatilityMember 2021-06-30 0001830547 us-gaap:MeasurementInputExpectedTermMember 2021-06-30 0001830547 us-gaap:MeasurementInputExercisePriceMember 2021-06-30 0001830547 ssaau:MeasurementInputNumberOfTrialsMember 2021-06-30 0001830547 us-gaap:MeasurementInputSharePriceMember 2021-01-28 0001830547 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-01-28 0001830547 us-gaap:MeasurementInputPriceVolatilityMember 2021-01-28 0001830547 us-gaap:MeasurementInputExpectedTermMember 2021-01-28 0001830547 us-gaap:MeasurementInputExercisePriceMember 2021-01-28 0001830547 ssaau:MeasurementInputNumberOfTrialsMember 2021-01-28 0001830547 us-gaap:CommonClassBMember 2020-12-31 0001830547 ssaau:CommonClassaNotSubjectToRedemptionMember 2020-12-31 0001830547 ssaau:FounderSharesMember ssaau:SponsorMember us-gaap:CommonClassBMember 2021-01-25 2021-01-25 0001830547 ssaau:PublicWarrantsMember us-gaap:IPOMember 2021-01-28 0001830547 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-06-30 0001830547 us-gaap:OverAllotmentOptionMember 2021-01-28 2021-01-28 0001830547 us-gaap:IPOMember 2021-01-25 2021-01-25 0001830547 us-gaap:CommonClassAMember 2021-01-01 2021-03-31 0001830547 ssaau:PrivatePlacementWarrantsMember 2021-01-01 2021-03-31 0001830547 ssaau:FounderSharesMember ssaau:SponsorMember us-gaap:CommonClassBMember 2021-01-01 2021-06-30 0001830547 ssaau:PrivatePlacementWarrantsMember 2021-01-01 2021-06-30 0001830547 ssaau:AdministrativeSupportAgreementMember 2021-01-01 2021-06-30 0001830547 ssaau:PublicWarrantsMember us-gaap:CommonClassAMember 2021-01-01 2021-06-30 0001830547 us-gaap:IPOMember 2021-01-28 2021-01-28 0001830547 ssaau:PublicWarrantsMember us-gaap:IPOMember 2021-01-28 2021-01-28 0001830547 ssaau:RelatedPartyLoansMember 2021-06-30 0001830547 ssaau:PromissoryNoteWithRelatedPartyMember 2020-10-29 0001830547 2021-01-28 0001830547 us-gaap:CommonClassBMember 2021-01-01 2021-06-30 0001830547 us-gaap:CommonClassBMember 2021-06-30 0001830547 ssaau:CommonClassaNotSubjectToRedemptionMember 2021-06-30 0001830547 ssaau:WorkingCapitalLoansWarrantMember ssaau:RelatedPartyLoansMember 2021-06-30 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2021-06-30 0001830547 ssaau:PrivatePlacementWarrantsMember us-gaap:PrivatePlacementMember 2021-01-28 0001830547 ssaau:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member ssaau:PublicWarrantsMember 2021-01-01 2021-06-30 0001830547 ssaau:RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member ssaau:PublicWarrantsMember 2021-01-01 2021-06-30 0001830547 ssaau:PublicWarrantsMember 2021-01-01 2021-06-30 0001830547 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001830547 2021-04-01 2021-06-30 0001830547 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001830547 2021-01-01 2021-03-31 0001830547 ssaau:CommonClassaNotSubjectToRedemptionMember 2021-04-01 2021-06-30 0001830547 ssaau:CommonClassaNotSubjectToRedemptionMember 2021-01-01 2021-03-31 0001830547 ssaau:FounderSharesMember ssaau:SponsorMember us-gaap:CommonClassBMember 2021-01-25 0001830547 2021-06-30 0001830547 2020-12-31 0001830547 us-gaap:CommonClassAMember 2021-01-01 2021-06-30 0001830547 ssaau:WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceMember 2021-01-01 2021-06-30 0001830547 ssaau:UnitEachConsistingOfOneClassCommonStockAndOneThirdRedeemableWarrantMember 2021-01-01 2021-06-30 0001830547 us-gaap:CommonClassBMember 2021-08-10 0001830547 us-gaap:CommonClassAMember 2021-08-10 0001830547 2021-01-01 2021-06-30 shares iso4217:USD pure iso4217:USD shares ssaau:item ssaau:Vote 0001830547 --12-31 2021 Q2 false 0 0 2809902 7762500 7762500 0 0.33 0 2809902 7762500 0 0 10-Q true 2021-06-30 false 001-39930 Science Strategic Acquisition Corp. Alpha DE 85-3594633 1447 2nd Street Santa Monica CA 90401 310 393-3024 Units, each consisting of one share of Class A common stock, $0.0001 par value, and one-third of one redeemable warrant SSAAU NASDAQ Class A common stock Class A common stock SSAA NASDAQ Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 SSAAW NASDAQ Yes Yes Non-accelerated Filer true true false true 31050000 7762500 868722 20000 183912 566520 1435242 203912 310534744 311969986 203912 135000 151812 27100 7018 5000 142018 183912 13534768 10867500 24544286 183912 28240098 0 282425690 0.0001 0.0001 1000000 1000000 0 0 0.0001 0.0001 400000000 400000000 2809902 0 28240098 0 281 0.0001 0.0001 40000000 40000000 7762500 7762500 776 776 7627684 24224 -2628731 -5000 5000010 20000 311969986 203912 211844 729474 -211844 -729474 6774 34744 3986035 1929002 -3979261 -1894258 -3979261 -1894258 -4191105 -2623732 28659098 28579419 0.00 0.00 10153402 9694261 -0.41 -0.27 7762500 776 24224 -5000 20000 31050000 31050000 3105 281816326 281819431 5473333 8210000 8210000 28462472 2846 284621874 284624720 196626 20 1992055 1992075 1567374 1567374 2390902 239 7762500 776 3436621 1562374 5000010 419000 42 4191063 4191105 -4191105 -4191105 2809902 281 7762500 776 7627684 -2628731 5000010 -2623732 34744 1929002 566520 2018 -1293976 310500000 -310500000 304710744 8210000 300000 300000 278046 312642698 848722 20000 868722 -2199030 284624720 11605766 135000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 1. ORGANIZATION AND PLANS OF BUSINESS OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Organization and General</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Science Strategic Acquisition Corp. Alpha (the “Company”) was incorporated in Delaware on October 22, 2020. The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (a “Business Combination”). The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sponsor and Initial Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2021, the Company had not commenced any operations. All activity through June 30, 2021 relates to the Company’s formation, the initial public offering (the “Initial Public Offering”), which is described below, and identifying a target for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The registration statements for the Initial Public Offering were declared effective on January 25, 2021. On January 28, 2021, the Company consummated the Initial Public Offering of 31,050,000 units (the “Units” and, with respect to the shares of Class A common stock included in the Units sold, the “Public Shares”), which includes the exercise by the underwriter of its over-allotment option in the amount of 4,050,000 Units, at $10.00 per Unit, generating gross proceeds of $310,500,000, which is described in Note 3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 5,473,333 warrants (each, a “Private Placement Warrant” and, collectively, the “Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant in a private placement to SSAC Alpha Sponsor, LLC (the “Sponsor”), generating gross proceeds of $8,210,000, which is described in Note 4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Transaction costs amounted to $17,495,500, consisting of $6,210,000 of underwriting fees, $10,867,500 of deferred underwriting fees and $418,000 of other offering costs. In addition, cash of approximately $2,300,000 was held outside of the Trust Account (as defined below) and is available for the payment of offering costs and for working capital purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Trust Account</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Following the closing of the Initial Public Offering on January 28, 2021, an amount of $310,500,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the “Trust Account”). The funds in the Trust Account will be invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended. The Company will not be permitted to withdraw any of the principal or interest held in the Trust Account except for the withdrawal of interest to pay taxes, if any. The funds held in the Trust Account will not otherwise be released from the trust account until the earliest of: (1) the Company’s completion of a Business Combination; (2) the redemption of any Public Shares properly submitted in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with a Business Combination or to redeem 100% of the Company’s Public Shares if the Company does not complete a Business Combination on or before January 28, 2023 or (B) with respect to any other provision relating to stockholders’ rights or pre-initial business combination activity; and (3) the redemption of the Company’s Public Shares if the Company has not completed a Business Combination on or before January 28, 2023, subject to applicable law. Based on current interest rates, the Company expects that interest earned on the trust account will be sufficient to pay taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business Combination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company’s management has broad discretion with respect to the specific application of the net proceeds from the Initial Public Offering, although substantially all of the net proceeds from the Initial Public Offering are intended to be generally applied toward consummating a Business Combination with (or acquisition of) a Target Business. As used herein, “Target Business” means one or more target businesses that together have an aggregate fair market value equal to at least 80% of the value of the assets held in the Trust Account (excluding taxes payable on the interest earned on the trust account) at the time of the signing of a definitive agreement in connection with a Business Combination. Furthermore, there is no assurance that the Company will be able to successfully effect a Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will provide its public stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination, either (i) in connection with a stockholder meeting called to approve such Business Combination or (ii) by means of a tender offer. The public stockholders will be entitled to redeem their shares for a pro rata portion of the amount held in the Trust Account, calculated as of two business days prior to the completion of a Business Combination, including any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. The per-share amount to be distributed to the public stockholders who redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter (as discussed in Note 6). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants. As a result, shares of common stock are recorded at their redemption amount and classified as temporary equity, in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, “Distinguishing Liabilities from Equity” (“ASC 480”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The decision as to whether the Company will seek stockholder approval of a Business Combination or will allow stockholders to sell their shares in a tender offer will be made by the Company, in its sole discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would otherwise require the Company to seek stockholder approval unless a vote is required by law or stock exchange listing requirements. If the Company seeks stockholder approval, it will complete its Business Combination only if a majority of the shares of common stock voted are voted in favor of a Business Combination. However, in no event will the Company redeem its Public Shares in an amount that would cause its net tangible assets to be less than $5,000,001 upon consummation of a Business Combination. In such case, the Company would not proceed with the redemption of its Public Shares and the related Business Combination, and instead may search for an alternate Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will have until January 28, 2023 to complete its initial Business Combination. If the Company does not complete a Business Combination by such date (or such longer period as provided in an amendment to the Company’s amended and restated certificate of incorporation approved by its stockholders (an “Extension Period”)), it shall (i) cease all operations except for the purposes of winding up; (ii) as promptly as reasonably possible but not more than 10 business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $100,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and its board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete its initial Business Combination by January 28, 2023 or during any Extension Period. The initial stockholders have entered into a letter agreement with the Company, pursuant to which they have waived their rights to liquidating distributions from the Trust Account with respect to their Founder Shares (as defined in Note 5) if the Company fails to complete its initial Business Combination by January 28, 2023 or during any Extension Period. However, if the initial stockholders acquire Public Shares, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete its initial Business Combination by January 28, 2023 or during any Extension Period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company’s independent auditors) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.00 per Public Share or (2) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, due to reductions in value of the trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriter of the Initial Public Offering against certain liabilities, including liabilities </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third party, then the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to have all third parties, including, but not limited to, all vendors, service providers (other than its independent registered public accounting firm), prospective target businesses and other entities with which the Company does business execute agreements with the Company waiving any right, title, interest or claims of any kind in or to any monies held in the Trust Account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity and Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2021, the Company had $868,722 cash held outside of the Trust Account and working capital of $1,293,227. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company’s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through the payment of $25,000 from the Sponsor to cover certain offering costs on the Company’s behalf in exchange for the issuance of Founder Shares (as discussed in Note 5), and a loan from the Sponsor of $300,000 under the Promissory Note (as discussed in Note 5). The Company repaid the Promissory Note in full on February 2, 2021. Subsequent to the consummation of the Initial Public Offering, the Company’s liquidity has been satisfied through the net proceeds from the consummation of the Initial Public Offering and the private placement held outside of the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (as discussed in Note 5). As of June 30, 2021, there were no working capital loans outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of a Business Combination or one year from the date the financial statements are issued. Over this time period, the Company will use these funds to pay existing accounts payable, identify and evaluate prospective initial Business Combination candidates, perform due diligence on prospective target businesses, pay for travel expenditures, select a target business to merge with or acquire, and structure, negotiate and consummate the Business Combination.</p> 31050000 4050000 10.00 310500000 5473333 1.50 8210000 17495500 6210000 10867500 418000 2300000 310500000 10.00 1 0.80 2 5000001 P10D 100000 10.00 868722 1293227 25000 300000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;"> </span>NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on April 7, 2021, which contains the audited financial statements and notes thereto. The financial information as of December 31, 2020 is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The interim results for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Emerging Growth Company</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is either not an emerging growth company or an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. Cash equivalents consist of mutual funds. The Company did not have any cash equivalents as of June 30, 2021 and December 31, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Offering Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Offering costs consist of legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial Public Offering. These costs, together with the upfront underwriting discounts, the deferred underwriting commissions and the financial advisory fee in connection with the Initial Public Offering were charged to stockholders’ equity and warrants exercisable for Class A common stock upon the completion of the Initial Public Offering. Approximately $17.1 million of the offering costs were related to the issuance of Class A common stock and charged to stockholders’ equity and approximately $0.4 million of the offering costs were related to the warrant liabilities and charged to the condensed statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Marketable Securities Held in Trust Account</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At June 30, 2021, substantially all of the assets held in the Trust Account were held in money market funds which invest in United States Treasury securities.Through June 30, 2021, the Company has not withdrawn any monies from the Trust Account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Class A Common Stock Subject to Possible Redemption</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC 480. Shares of Class A common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s Class A common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at June 30, 2021, Class A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2021 and December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) into law. The CARES Act includes several significant business tax provisions that, among other things, would eliminate the taxable income limit for certain net operating losses (“NOL”) and allow businesses to carry back NOLs arising in 2018, 2019 and 2020 to the five prior years, suspend the excess business loss rules, accelerate refunds of previously generated corporate alternative minimum tax credits, generally loosen the business interest limitation under section 163(j) of the Internal Revenue Code of 1986, as amended, from 30 percent to 50 percent among other technical corrections included in the Tax Cuts and Jobs Act tax provisions. The Company does not believe that the CARES Act will have a significant impact on Company's financial position or statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Net Loss per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Shares of common stock subject to possible redemption at June 30, 2021, which are not currently redeemable and are not redeemable at fair value, have been excluded from the calculation of basic net loss per common share since such shares, if redeemed, only participate in their pro rata share of the Trust Account earnings. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the private placement to purchase an aggregate of 15,823,333 shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. As a result, diluted net loss per common share is the same as basic net loss per common share for the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company’s statement of operations includes a presentation of net earnings (loss) per share for common shares subject to possible redemption and applies the two-class method in calculating net earnings (loss) per share. Net earnings per common share, basic and diluted, for Class A redeemable common stock is calculated by dividing the allocable interest income earned on the Trust Account, net of applicable franchise and income taxes, by the weighted average number of Class A common stock subject to possible redemption outstanding since original issuance. Net loss per share, basic and diluted, for Class A and Class B non-redeemable common stock is calculated by dividing the net loss, adjusted for income attributable to Class A redeemable common stock, by the weighted average number of Class A and Class B non-redeemable common stock outstanding for the period. Class B non-redeemable common stock includes the Founder Shares as these shares do not have any redemption features and do not participate in the income earned on the Trust Account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The following table reflects the calculation of basic and diluted net earnings (loss) per common share (in dollars, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ended</b> </p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Class A Common Stock subject to possible redemption</i></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Numerator: Earnings attributable to Class A Common Stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized gain on marketable securities held in Trust Account</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,929</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,280</p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net earnings attributable to Class A Common Stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,280</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Denominator: Weighted average Class A Common Stock subject to possible redemption</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted weighted average shares outstanding, Class A Common Stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,659,098</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,579,419</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net earnings per share, Class A Common Stock subject to possible redemption</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Non-Redeemable Class A and Class B Common Stock</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Numerator: Net loss minus net earnings</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,191,105)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,623,732)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Less: Net earnings attributable to Class A Common Stock subject to possible redemption</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,929)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,280)</p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Non-redeemable net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,196,034)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,649,012)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Denominator: Weighted average Non-Redeemable Class A and Class B Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Basic and diluted weighted average shares outstanding, Non-Redeemable Class A and Class B Common Stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,153,402</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,694,261</p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share, Non-Redeemable Class A and Class B Common Stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.41)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.27)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurement” (“ASC 820”), approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants Exercisable for Class A Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounted for the 15,823,333 warrants issued in connection with the Initial Public Offering and the Private Placement Warrants (collectively, the “Warrants”) as either equity-classified or liability-classified instruments based on an assessment of the Warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the company’s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s condensed financial statements.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on April 7, 2021, which contains the audited financial statements and notes thereto. The financial information as of December 31, 2020 is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The interim results for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Emerging Growth Company</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is either not an emerging growth company or an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of the condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. Cash equivalents consist of mutual funds. The Company did not have any cash equivalents as of June 30, 2021 and December 31, 2020.</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Offering Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Offering costs consist of legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial Public Offering. These costs, together with the upfront underwriting discounts, the deferred underwriting commissions and the financial advisory fee in connection with the Initial Public Offering were charged to stockholders’ equity and warrants exercisable for Class A common stock upon the completion of the Initial Public Offering. Approximately $17.1 million of the offering costs were related to the issuance of Class A common stock and charged to stockholders’ equity and approximately $0.4 million of the offering costs were related to the warrant liabilities and charged to the condensed statement of operations.</p> 17100000 400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Marketable Securities Held in Trust Account</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At June 30, 2021, substantially all of the assets held in the Trust Account were held in money market funds which invest in United States Treasury securities.Through June 30, 2021, the Company has not withdrawn any monies from the Trust Account.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Class A Common Stock Subject to Possible Redemption</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC 480. Shares of Class A common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s Class A common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at June 30, 2021, Class A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2021 and December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) into law. The CARES Act includes several significant business tax provisions that, among other things, would eliminate the taxable income limit for certain net operating losses (“NOL”) and allow businesses to carry back NOLs arising in 2018, 2019 and 2020 to the five prior years, suspend the excess business loss rules, accelerate refunds of previously generated corporate alternative minimum tax credits, generally loosen the business interest limitation under section 163(j) of the Internal Revenue Code of 1986, as amended, from 30 percent to 50 percent among other technical corrections included in the Tax Cuts and Jobs Act tax provisions. The Company does not believe that the CARES Act will have a significant impact on Company's financial position or statement of operations.</p> 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Net Loss per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Shares of common stock subject to possible redemption at June 30, 2021, which are not currently redeemable and are not redeemable at fair value, have been excluded from the calculation of basic net loss per common share since such shares, if redeemed, only participate in their pro rata share of the Trust Account earnings. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the private placement to purchase an aggregate of 15,823,333 shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. As a result, diluted net loss per common share is the same as basic net loss per common share for the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company’s statement of operations includes a presentation of net earnings (loss) per share for common shares subject to possible redemption and applies the two-class method in calculating net earnings (loss) per share. Net earnings per common share, basic and diluted, for Class A redeemable common stock is calculated by dividing the allocable interest income earned on the Trust Account, net of applicable franchise and income taxes, by the weighted average number of Class A common stock subject to possible redemption outstanding since original issuance. Net loss per share, basic and diluted, for Class A and Class B non-redeemable common stock is calculated by dividing the net loss, adjusted for income attributable to Class A redeemable common stock, by the weighted average number of Class A and Class B non-redeemable common stock outstanding for the period. Class B non-redeemable common stock includes the Founder Shares as these shares do not have any redemption features and do not participate in the income earned on the Trust Account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The following table reflects the calculation of basic and diluted net earnings (loss) per common share (in dollars, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ended</b> </p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Class A Common Stock subject to possible redemption</i></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Numerator: Earnings attributable to Class A Common Stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized gain on marketable securities held in Trust Account</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,929</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,280</p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net earnings attributable to Class A Common Stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,280</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Denominator: Weighted average Class A Common Stock subject to possible redemption</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted weighted average shares outstanding, Class A Common Stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,659,098</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,579,419</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net earnings per share, Class A Common Stock subject to possible redemption</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Non-Redeemable Class A and Class B Common Stock</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Numerator: Net loss minus net earnings</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,191,105)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,623,732)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Less: Net earnings attributable to Class A Common Stock subject to possible redemption</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,929)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,280)</p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Non-redeemable net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,196,034)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,649,012)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Denominator: Weighted average Non-Redeemable Class A and Class B Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Basic and diluted weighted average shares outstanding, Non-Redeemable Class A and Class B Common Stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,153,402</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,694,261</p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share, Non-Redeemable Class A and Class B Common Stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.41)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.27)</p></td></tr></table> 15823333 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ended</b> </p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Class A Common Stock subject to possible redemption</i></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Numerator: Earnings attributable to Class A Common Stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized gain on marketable securities held in Trust Account</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,929</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,280</p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net earnings attributable to Class A Common Stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,280</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Denominator: Weighted average Class A Common Stock subject to possible redemption</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted weighted average shares outstanding, Class A Common Stock subject to possible redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,659,098</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,579,419</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net earnings per share, Class A Common Stock subject to possible redemption</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.00</p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Non-Redeemable Class A and Class B Common Stock</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Numerator: Net loss minus net earnings</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,191,105)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,623,732)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Less: Net earnings attributable to Class A Common Stock subject to possible redemption</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,929)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,280)</p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Non-redeemable net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,196,034)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,649,012)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Denominator: Weighted average Non-Redeemable Class A and Class B Common Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Basic and diluted weighted average shares outstanding, Non-Redeemable Class A and Class B Common Stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,153,402</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,694,261</p></td></tr><tr><td style="vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:70.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per share, Non-Redeemable Class A and Class B Common Stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.41)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.27)</p></td></tr></table> 4929 25280 4929 25280 28659098 28579419 0.00 0.00 -4191105 -2623732 -4929 -25280 -4196034 -2649012 10153402 9694261 -0.41 -0.27 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.</p> 250000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Fair Value of Financial Instruments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurement” (“ASC 820”), approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants Exercisable for Class A Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company accounted for the 15,823,333 warrants issued in connection with the Initial Public Offering and the Private Placement Warrants (collectively, the “Warrants”) as either equity-classified or liability-classified instruments based on an assessment of the Warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the company’s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</p> 15823333 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s condensed financial statements.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 3. INITIAL PUBLIC OFFERING</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">On January 28, 2021, pursuant to the Initial Public Offering, the Company sold 31,050,000 Units, which includes the full exercise by the underwriter of its over-allotment option in the amount of 4,050,000 Units, at a price of $10.00 per Unit. Each Unit consists of one share of Class A common stock and <span style="-sec-ix-hidden:Hidden_yEh4bYKhGESEP6Cp9ebOoQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">one</span></span>-third of one (each whole warrant, a “Public Warrant”). Each whole Public Warrant entitles the holder to purchase one share of Class A common stock at an exercise price of $11.50 per share, subject to adjustment (see Note 8).</p> 31050000 4050000 10.00 1 1 11.50 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 4. PRIVATE PLACEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 5,473,333 Private Placement Warrants, at a price of $1.50 per Private Placement Warrant, for an aggregate purchase price of $8,210,000 in a private placement. Each Private Placement Warrant is exercisable to purchase one share of Class A common stock at an exercise price of $11.50 per share. $6,210,000 of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination by January 28, 2023 or during any Extension Period, the proceeds of the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Placement Warrants.</p> 5473333 1.50 8210000 1 11.50 6210000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 5. RELATED PARTY TRANSACTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Founder Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 29, 2020, the Sponsor purchased 6,468,750 Founder Shares (as defined below) for an aggregate purchase price of $25,000. On January 25, 2021, the Company effected a stock dividend of 1,293,750 shares of Class B common stock to holders of Class B common stock on a pro rata basis based on their holdings, resulting in the Company’s initial stockholders holding an aggregate of 7,762,500 Founder Shares. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The initial stockholders have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Class B common stock or Class A common stock received upon conversion thereof (together, “Founder Shares”) until the earlier of: (A) one year after the completion of a Business Combination; and (B) subsequent to a Business Combination (x) if the last reported sale price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, rights issuances, consolidations, reorganizations, recapitalizations and other similar transactions) for any 20 trading days within any 30-trading day period commencing at least 150 days after a Business Combination or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the Company’s public stockholders having the right to exchange their shares of common stock for cash, securities or other property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Promissory Note — Related Party</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 29, 2020, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the “Promissory Note”). The Promissory Note was non-interest bearing and payable on the earlier of December 31, 2021 or the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $300,000 remained outstanding at the closing of the Initial Public Offering on January 28, 2021. On February 2, 2021, the Company repaid the Promissory Note in full.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Administrative Services Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company agreed, commencing on January 26, 2021 through the earlier of the Company’s consummation of a Business Combination and its liquidation, to pay an affiliate of the Sponsor a total of $10,000 per month for office space, administrative and support services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Related Party Loans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender's discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $1.50 per warrant. Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans.</p> 6468750 25000 1293750 7762500 P1Y 12.00 20 30 P150D 300000 300000 10000 1500000 1.50 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 6. COMMITMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Registration Rights</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued on conversion of Working Capital Loans (and any Class A common stock issuable upon the exercise of the Private Placement Warrants or warrants issued upon conversion of the Working Capital Loans and upon conversion of the Founder Shares) will be entitled to registration rights pursuant to a registration rights agreement to be signed prior to or on the effective date of the Initial Public Offering requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to the Company’s Class A common stock). The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until termination of the applicable lock-up period. The Company will bear the expenses incurred in connection with the filing of any such registration statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Underwriting Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The underwriters are entitled to a deferred fee of $0.35 per Unit, or $10,867,500 in the aggregate. The deferred fee will be waived by the underwriters in the event that the Company does not complete a Business Combination, subject to the terms of the underwriting agreement by January 28, 2023.</p> 3 0.35 10867500 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 7. STOCKHOLDERS’ EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preferred Stock</span><b style="font-weight:bold;"> </b>— The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share. The Company’s board of directors is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. The board of directors is able to, without stockholder approval, issue shares of preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of the common stock and could have anti-takeover effects. At June 30, 2021, there were no shares of preferred stock issued or <span style="-sec-ix-hidden:Hidden_TQKVa_irtUaY7qdhnxxyGQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">outstanding</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class A Common Stock</span><b style="font-weight:bold;"> </b>— The Company is authorized to issue 400,000,000 shares of Class A common stock with a par value of $0.0001 per share. Holders of Class A common stock are entitled to one vote for each share. At June 30, 2021, there were 2,809,902 shares of Class A common stock <span style="-sec-ix-hidden:Hidden_i4UGcpbI-ESzHWwBSSr1rg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">issued</span></span> and outstanding, excluding 28,240,098 shares of Class A common stock subject to possible redemption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Class B Common Stock</span><b style="font-weight:bold;"> </b>—The Company is authorized to issue 40,000,000 shares of Class B common stock with a par value of $0.0001 per share. Holders of Class B common stock are entitled to one vote for each share. At June 30, 2021, there were 7,762,500 shares of Class B common stock <span style="-sec-ix-hidden:Hidden_8TV4Ip-pbkWJLqSg-EgwKg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">issued</span></span> and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of Class B common stock have the right to elect all of the Company’s directors prior to a Business Combination. Holders of Class A common stock and Class B common stock will vote together as a single class on all other matters submitted to a vote of stockholders except as required by law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Class B common stock will automatically convert into Class A common stock at the time of the completion of a Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts issued in the Initial Public </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Offering and related to the closing of a Business Combination, the ratio at which Founder Shares will convert into Class A common stock will be adjusted (subject to waiver by holders of a majority of the Class B common stock) so that the number of shares of Class A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of the common stock issued and outstanding upon completion of the Initial Public Offering plus the number of shares of Class A common stock and equity-linked securities issued or deemed issued in connection with a Business Combination, excluding any shares of Class A common stock or equity-linked securities issued, or to be issued, to any seller in a Business Combination.</p> 1000000 0.0001 0 400000000 0.0001 1 2809902 28240098 40000000 0.0001 1 7762500 1 20 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 8. WARRANTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warrants </span>— Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants and only whole warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months after the closing of the Initial Public Offering. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement governing the Warrants (the “Warrant Agreement”). The exercise price and number of shares of Class A common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However except as described below, the warrants will not be adjusted for issuances of Class A common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of the warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution form the Company’s assets held outside the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if (x) the Company issues additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of the Company’s initial Business Combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by our board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any founder shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Company’s initial Business Combination on the date of the completion of the Company’s initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of shares of the Company’s Class A common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummate a Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described below under “Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $18.00” and “Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described below under “Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the Public Warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration or a valid exemption from registration is available. No Public Warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their Public Warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption from registration is available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company has agreed that as soon as practicable, but in no event later than 15 business days, after the closing of a Business Combination, it will use its commercially reasonable efforts to file with the SEC a registration statement registering the issuance, under the Securities Act, of the Class A common stock issuable upon exercise of the Public Warrants. The Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of a Business Combination and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the Public Warrants in accordance with the provisions of the Warrant Agreement. Notwithstanding the above, if the Class A common stock is, at </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the time of any exercise of a Public Warrant, not listed on a national securities exchange such that they do not satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their Public Warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $18.00. Once the Public Warrants become exercisable, the Company may redeem the Public Warrants:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">in whole and not in part;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">at a price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$0.01</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per Public Warrant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">upon not less than </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">30 days</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">' prior written notice of redemption to each warrant holder; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">if, and only if, the last reported sale price of shares of the Class A common stock for any </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">20</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> trading days within a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">30</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> -trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the “Reference Value”) equals or exceeds </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">$18.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant).</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $10.00. Once the Public Warrants become exercisable, the Company may redeem the Public Warrants:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">in whole and not in part;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">at $0.10 </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">per warrant upon a minimum of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">30 days</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the “fair market value” of the Class A common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">if, and only if, the Reference Value equals or exceeds $10.00 </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">per share (as adjusted); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">if the Reference Value is less than $18.00 </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">per share (as adjusted), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If and when the Public Warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Private Placement Warrants are identical to the Public Warrants underlying the Units that were sold in the Initial Public Offering, except that the Private Placement Warrants and the Class A common stock issuable upon the exercise of the Private Placement Warrants are not transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants are exercisable on a cashless basis and are non-redeemable, except as described above, so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants are redeemable by the Company and are exercisable by such holders on the same basis as the Public Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Warrants are not considered to be indexed to the Company’s stock price. In accordance with FASB ASC 815, the warrants were classified as a liability in the total amount of $11.6 million at January 28, 2021. In addition, the warrants must be valued every reporting period and adjusted to market with the increase or decrease being adjusted through earnings. As of June 30, 2021 the fair value of the warrant liability was $13.5 million.</p> P30D P12M P5Y 9.20 0.60 20 9.20 1.15 18.00 18.00 10.00 1.80 10.00 10.00 P15D P60D 18.00 0.01 P30D 20 30 18.00 10.00 0.10 P30D 10.00 18.00 P30D 11600000 13500000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 9. FAIR VALUE MEASUREMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">Level 1:</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">Level 2:</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">Level 3:</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Level 1 assets and liabilities at fair value is comprised of Cash, Cash held in the Trust Account and Public Warrants. The company has no other Level 1 assets or liabilities at fair value and no Level 2 assets or liabilities at fair value at June 30, 2021 and December 31, 2020. The Company has warrants exercisable for Class A common stock with a fair value of $13,534,768 and $0 as of June 30, 2021 and December 31, 2020, respectively. The Private Placement Warrants are classified as Level 3 based on a valuation model that utilizes both observable and unobservable inputs. Observable inputs include market prices of warrants issued by other special purpose acquisition companies and unobservable inputs include model adjustments for valuation uncertainty pertaining to the probability of the Company consummating a Business Combination. There were <span style="-sec-ix-hidden:Hidden_f7IoGMhVjk2rTZc6sTBabw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">no</span></span> transfers into or <span style="-sec-ix-hidden:Hidden_UK0w61PynkKOatXim2cYbg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">out</span></span> of Level 3 within the fair value hierarchy during the three and six month periods ended June 30, 2021. The following table provides a summary of the changes in fair value of the Company’s Level 3 assets and liabilities for the six months ended June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Private Placement Warrants</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable for</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A common</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">stock</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Initial fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,050,266</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes in fair value of warrant liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (711,533)</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at March 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,338,733</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in fair value of warrant liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,342,979</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at June 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,681,712</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at June 30, 2021 and December 31, 2020, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:63.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities held in Trust Account</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 310,534,744</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:63.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Public warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,853,056</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Private warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,681,712</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Warrants were initially valued using a Monte Carlo simulation model, with the observable assumptions as provided in the table below. Significant increases in the expected stock prices and expected liquidity would result in a significantly higher fair value measurement. Significant increases in either the probability or severity of default of the host instrument would result in a significantly lower fair value measurement. The measurement of the Public Warrants after the detachment of the Public Warrants from the Units is classified as Level 1 due to the use of an observable market quote in an active market. For periods subsequent to the detachment of the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Public Warrants from the Units, the closing price of the Public Warrant was used as the fair value for the Public Warrants as of each relevant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">January 28,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock price on valuation date</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.76</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.71</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Term (years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.93</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.09</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.57</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.05</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 13534768 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:75.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Private Placement Warrants</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable for</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Class A common</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:22.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">stock</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance December 31, 2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Initial fair value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,050,266</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes in fair value of warrant liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (711,533)</p></td></tr><tr><td style="vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at March 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,338,733</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in fair value of warrant liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,342,979</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value at June 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,681,712</p></td></tr></table> 4050266 -711533 3338733 1342979 4681712 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:63.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities held in Trust Account</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 310,534,744</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:63.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Public warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,853,056</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Private warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,681,712</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table> 310534744 8853056 4681712 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Public Warrants from the Units, the closing price of the Public Warrant was used as the fair value for the Public Warrants as of each relevant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">January 28,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock price on valuation date</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.76</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.71</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Term (years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.93</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.09</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average risk-free interest rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.57</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.05</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:72.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 9.76 9.71 11.50 11.50 5.93 6.09 14.0 13.3 0.57 1.05 400 400 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 10. SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements.</p> XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2021
Aug. 10, 2021
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Jun. 30, 2021  
Entity File Number 001-39930  
Entity Registrant Name Science Strategic Acquisition Corp. Alpha  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 85-3594633  
Entity Address, Address Line One 1447 2nd Street  
Entity Address, City or Town Santa Monica  
Entity Address State Or Province CA  
Entity Address, Postal Zip Code 90401  
City Area Code 310  
Local Phone Number 393-3024  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company true  
Entity Central Index Key 0001830547  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Unit Each Consisting Of One Class Common Stock And One Third of one Redeemable Warrant    
Document Information [Line Items]    
Title of 12(b) Security Units, each consisting of one share of Class A common stock, $0.0001 par value, and one-third of one redeemable warrant  
Trading Symbol SSAAU  
Security Exchange Name NASDAQ  
Class A Common Stock    
Document Information [Line Items]    
Title of 12(b) Security Class A common stock  
Trading Symbol SSAA  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   31,050,000
Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50    
Document Information [Line Items]    
Title of 12(b) Security Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50  
Trading Symbol SSAAW  
Security Exchange Name NASDAQ  
Class B Common Stock    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   7,762,500
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Balance Sheets - USD ($)
Jun. 30, 2021
Dec. 31, 2020
Current assets    
Cash $ 868,722 $ 20,000
Deferred offering costs   183,912
Prepaid expenses 566,520  
Total Current Assets 1,435,242 203,912
Marketable securities held in Trust Account 310,534,744  
TOTAL ASSETS 311,969,986 203,912
Current liabilities    
Accrued offering costs 135,000 151,812
Accrued offering costs - related party   27,100
Accrued expenses 7,018 5,000
Total Current Liabilities 142,018 183,912
Warrant liability 13,534,768 0
Deferred underwriting fee payable 10,867,500  
Total Liabilities 24,544,286 183,912
Commitments
Stockholders' Equity    
Preferred stock, $0.0001 par value; 1,000,000 authorized; none issued and outstanding
Additional paid-in capital 7,627,684 24,224
Accumulated deficit (2,628,731) (5,000)
Total Stockholders' Equity 5,000,010 20,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY 311,969,986 203,912
Class A Common Stock Subject to Redemption    
Current liabilities    
Class A Common stock subject to possible redemption, 28,240,098 and no shares at redemption value as of June 30, 2021 and December 31, 2020, respectively 282,425,690  
Class A Common Stock Not Subject to Redemption    
Stockholders' Equity    
Common stock 281  
Total Stockholders' Equity 281  
Class B Common Stock    
Stockholders' Equity    
Common stock 776 776
Total Stockholders' Equity $ 776 $ 776
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2021
Dec. 31, 2020
Preferred stock, par value, (per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Class A Common Stock Subject to Redemption    
Temporary equity, shares issued 28,240,098 0
Temporary equity, shares outstanding 28,240,098 0
Class A Common Stock Not Subject to Redemption    
Common shares, par value, (per share) $ 0.0001 $ 0.0001
Common shares, shares authorized 400,000,000 400,000,000
Common shares, shares issued 2,809,902 0
Common shares, shares outstanding 2,809,902 0
Class B Common Stock    
Common shares, par value, (per share) $ 0.0001 $ 0.0001
Common shares, shares authorized 40,000,000 40,000,000
Common shares, shares issued 7,762,500 7,762,500
Common shares, shares outstanding 7,762,500 7,762,500
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Statement of Operations - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2021
Operating costs $ 211,844 $ 729,474
Loss from operations (211,844) (729,474)
Other income (loss):    
Unrealized gain on marketable securities held in Trust Account 6,774 34,744
Change in fair value of warrant liability (3,986,035) (1,929,002)
Other income (loss), net (3,979,261) (1,894,258)
Loss before provision for income taxes (3,979,261) (1,894,258)
Net Loss $ (4,191,105) $ (2,623,732)
Class A Common Stock Subject to Redemption    
Other income (loss):    
Weighted average shares outstanding, basic and diluted 28,659,098 28,579,419
Basic and diluted net loss per share $ 0.00 $ 0.00
Non redeemable Class A and Class B Common Stock    
Other income (loss):    
Net Loss $ (4,191,105) $ (2,623,732)
Weighted average shares outstanding, basic and diluted 10,153,402 9,694,261
Basic and diluted net loss per share $ (0.41) $ (0.27)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Statement of Operations (Parenthetical) - shares
Jun. 30, 2021
Dec. 31, 2020
Class A Common Stock Subject to Redemption    
Temporary equity, shares outstanding 28,240,098 0
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Statement of Changes in Stockholders' Equity - USD ($)
Class A Common Stock
Class A Common Stock Not Subject to Redemption
Class B Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Balance at the beginning at Dec. 31, 2020     $ 776 $ 24,224 $ (5,000) $ 20,000
Balance at the beginning (in shares) at Dec. 31, 2020     7,762,500      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Sale of 31,050,000 Units, net of underwriting discount and offering expenses   $ 3,105   281,816,326   281,819,431
Sale of 31,050,000 Units, net of underwriting discount and offering expenses (in shares) 31,050,000 31,050,000        
Sale of 5,473,333 private placement warrants       8,210,000   8,210,000
Common stock subject to possible redemption   $ (2,846)   (284,621,874)   (284,624,720)
Common stock subject to possible redemption (in shares)   (28,462,472)        
Change in value of common stock subject to possible redemption   $ 20   1,992,055   1,992,075
Change in value of common stock subject to possible redemption (in shares)   196,626        
Net income (loss)         1,567,374 1,567,374
Balance at the end at Mar. 31, 2021   $ 239 $ 776 3,436,621 1,562,374 5,000,010
Balance at the end (in shares) at Mar. 31, 2021   2,390,902 7,762,500      
Balance at the beginning at Dec. 31, 2020     $ 776 24,224 (5,000) 20,000
Balance at the beginning (in shares) at Dec. 31, 2020     7,762,500      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss)           (2,623,732)
Balance at the end at Jun. 30, 2021   $ 281 $ 776 7,627,684 (2,628,731) 5,000,010
Balance at the end (in shares) at Jun. 30, 2021   2,809,902 7,762,500      
Balance at the beginning at Mar. 31, 2021   $ 239 $ 776 3,436,621 1,562,374 5,000,010
Balance at the beginning (in shares) at Mar. 31, 2021   2,390,902 7,762,500      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Change in value of common stock subject to possible redemption   $ 42   4,191,063   4,191,105
Change in value of common stock subject to possible redemption (in shares)   419,000        
Net income (loss)         (4,191,105) (4,191,105)
Balance at the end at Jun. 30, 2021   $ 281 $ 776 $ 7,627,684 $ (2,628,731) $ 5,000,010
Balance at the end (in shares) at Jun. 30, 2021   2,809,902 7,762,500      
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Statement of Changes in Stockholders' Equity (Parenthetical) - shares
3 Months Ended
Jan. 28, 2021
Mar. 31, 2021
Jun. 30, 2021
Sale of Private Placement Warrants (in shares)     15,823,333
Private Placement Warrants      
Number of units sold   5,473,333  
Over-allotment option      
Number of units sold 4,050,000    
Private Placement | Private Placement Warrants      
Sale of Private Placement Warrants (in shares) 5,473,333   5,473,333
Class A Common Stock      
Number of units sold   31,050,000  
Class A Common Stock Not Subject to Redemption      
Number of units sold   31,050,000  
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Statement of Cash Flows
6 Months Ended
Jun. 30, 2021
USD ($)
Cash Flows used in Operating Activities:  
Net loss $ (2,623,732)
Adjustments to reconcile net income to net cash used in operating activities:  
Unrealized gain on marketable securities held in Trust Account (34,744)
Change in fair value of warrant liabilities 1,929,002
Changes in operating assets and liabilities:  
Prepaid expenses (566,520)
Accrued expenses 2,018
Net cash used in operating activities (1,293,976)
Cash Flows from Investing Activities:  
Investment of cash in Trust Account (310,500,000)
Net cash used in investing activities (310,500,000)
Cash Flows from Financing Activities:  
Proceeds from sale of Units, net of underwriting discounts paid 304,710,744
Proceeds from the sale of Private Placements Warrants 8,210,000
Proceeds from promissory note - related party 300,000
Repayment of promissory note - related party (300,000)
Payment of offering costs (278,046)
Net cash provided by financing activities 312,642,698
Net Change in Cash 848,722
Cash - Beginning of period 20,000
Cash - End of period 868,722
Non-cash investing and financing activities:  
Change in value of common stock subject to possible redemption (2,199,030)
Initial classification of common stock subject to redemption 284,624,720
Initial fair value of warrant liability 11,605,766
Deferred offering cost included in accrued offering cost $ 135,000
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION AND PLANS OF BUSINESS OPERATIONS
6 Months Ended
Jun. 30, 2021
ORGANIZATION AND PLANS OF BUSINESS OPERATIONS  
ORGANIZATION AND PLANS OF BUSINESS OPERATIONS

NOTE 1. ORGANIZATION AND PLANS OF BUSINESS OPERATIONS

Organization and General

Science Strategic Acquisition Corp. Alpha (the “Company”) was incorporated in Delaware on October 22, 2020. The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (a “Business Combination”). The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”).

Sponsor and Initial Financing

As of June 30, 2021, the Company had not commenced any operations. All activity through June 30, 2021 relates to the Company’s formation, the initial public offering (the “Initial Public Offering”), which is described below, and identifying a target for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering.

The registration statements for the Initial Public Offering were declared effective on January 25, 2021. On January 28, 2021, the Company consummated the Initial Public Offering of 31,050,000 units (the “Units” and, with respect to the shares of Class A common stock included in the Units sold, the “Public Shares”), which includes the exercise by the underwriter of its over-allotment option in the amount of 4,050,000 Units, at $10.00 per Unit, generating gross proceeds of $310,500,000, which is described in Note 3.

Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 5,473,333 warrants (each, a “Private Placement Warrant” and, collectively, the “Private Placement Warrants”) at a price of $1.50 per Private Placement Warrant in a private placement to SSAC Alpha Sponsor, LLC (the “Sponsor”), generating gross proceeds of $8,210,000, which is described in Note 4.

Transaction costs amounted to $17,495,500, consisting of $6,210,000 of underwriting fees, $10,867,500 of deferred underwriting fees and $418,000 of other offering costs. In addition, cash of approximately $2,300,000 was held outside of the Trust Account (as defined below) and is available for the payment of offering costs and for working capital purposes.

The Trust Account

Following the closing of the Initial Public Offering on January 28, 2021, an amount of $310,500,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the “Trust Account”). The funds in the Trust Account will be invested only in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended. The Company will not be permitted to withdraw any of the principal or interest held in the Trust Account except for the withdrawal of interest to pay taxes, if any. The funds held in the Trust Account will not otherwise be released from the trust account until the earliest of: (1) the Company’s completion of a Business Combination; (2) the redemption of any Public Shares properly submitted in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with a Business Combination or to redeem 100% of the Company’s Public Shares if the Company does not complete a Business Combination on or before January 28, 2023 or (B) with respect to any other provision relating to stockholders’ rights or pre-initial business combination activity; and (3) the redemption of the Company’s Public Shares if the Company has not completed a Business Combination on or before January 28, 2023, subject to applicable law. Based on current interest rates, the Company expects that interest earned on the trust account will be sufficient to pay taxes.

Business Combination

The Company’s management has broad discretion with respect to the specific application of the net proceeds from the Initial Public Offering, although substantially all of the net proceeds from the Initial Public Offering are intended to be generally applied toward consummating a Business Combination with (or acquisition of) a Target Business. As used herein, “Target Business” means one or more target businesses that together have an aggregate fair market value equal to at least 80% of the value of the assets held in the Trust Account (excluding taxes payable on the interest earned on the trust account) at the time of the signing of a definitive agreement in connection with a Business Combination. Furthermore, there is no assurance that the Company will be able to successfully effect a Business Combination.

The Company will provide its public stockholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination, either (i) in connection with a stockholder meeting called to approve such Business Combination or (ii) by means of a tender offer. The public stockholders will be entitled to redeem their shares for a pro rata portion of the amount held in the Trust Account, calculated as of two business days prior to the completion of a Business Combination, including any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. The per-share amount to be distributed to the public stockholders who redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriter (as discussed in Note 6). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants. As a result, shares of common stock are recorded at their redemption amount and classified as temporary equity, in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 480, “Distinguishing Liabilities from Equity” (“ASC 480”).

The decision as to whether the Company will seek stockholder approval of a Business Combination or will allow stockholders to sell their shares in a tender offer will be made by the Company, in its sole discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would otherwise require the Company to seek stockholder approval unless a vote is required by law or stock exchange listing requirements. If the Company seeks stockholder approval, it will complete its Business Combination only if a majority of the shares of common stock voted are voted in favor of a Business Combination. However, in no event will the Company redeem its Public Shares in an amount that would cause its net tangible assets to be less than $5,000,001 upon consummation of a Business Combination. In such case, the Company would not proceed with the redemption of its Public Shares and the related Business Combination, and instead may search for an alternate Business Combination.

The Company will have until January 28, 2023 to complete its initial Business Combination. If the Company does not complete a Business Combination by such date (or such longer period as provided in an amendment to the Company’s amended and restated certificate of incorporation approved by its stockholders (an “Extension Period”)), it shall (i) cease all operations except for the purposes of winding up; (ii) as promptly as reasonably possible but not more than 10 business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $100,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and its board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if the Company fails to complete its initial Business Combination by January 28, 2023 or during any Extension Period. The initial stockholders have entered into a letter agreement with the Company, pursuant to which they have waived their rights to liquidating distributions from the Trust Account with respect to their Founder Shares (as defined in Note 5) if the Company fails to complete its initial Business Combination by January 28, 2023 or during any Extension Period. However, if the initial stockholders acquire Public Shares, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete its initial Business Combination by January 28, 2023 or during any Extension Period.

The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company’s independent auditors) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.00 per Public Share or (2) such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, due to reductions in value of the trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriter of the Initial Public Offering against certain liabilities, including liabilities

under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third party, then the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to have all third parties, including, but not limited to, all vendors, service providers (other than its independent registered public accounting firm), prospective target businesses and other entities with which the Company does business execute agreements with the Company waiving any right, title, interest or claims of any kind in or to any monies held in the Trust Account.

Liquidity and Capital Resources

As of June 30, 2021, the Company had $868,722 cash held outside of the Trust Account and working capital of $1,293,227.

The Company’s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through the payment of $25,000 from the Sponsor to cover certain offering costs on the Company’s behalf in exchange for the issuance of Founder Shares (as discussed in Note 5), and a loan from the Sponsor of $300,000 under the Promissory Note (as discussed in Note 5). The Company repaid the Promissory Note in full on February 2, 2021. Subsequent to the consummation of the Initial Public Offering, the Company’s liquidity has been satisfied through the net proceeds from the consummation of the Initial Public Offering and the private placement held outside of the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (as discussed in Note 5). As of June 30, 2021, there were no working capital loans outstanding.

Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of a Business Combination or one year from the date the financial statements are issued. Over this time period, the Company will use these funds to pay existing accounts payable, identify and evaluate prospective initial Business Combination candidates, perform due diligence on prospective target businesses, pay for travel expenditures, select a target business to merge with or acquire, and structure, negotiate and consummate the Business Combination.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Jun. 30, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on April 7, 2021, which contains the audited financial statements and notes thereto. The financial information as of December 31, 2020 is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The interim results for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is either not an emerging growth company or an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates

The preparation of the condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. Cash equivalents consist of mutual funds. The Company did not have any cash equivalents as of June 30, 2021 and December 31, 2020.

Offering Costs

Offering costs consist of legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial Public Offering. These costs, together with the upfront underwriting discounts, the deferred underwriting commissions and the financial advisory fee in connection with the Initial Public Offering were charged to stockholders’ equity and warrants exercisable for Class A common stock upon the completion of the Initial Public Offering. Approximately $17.1 million of the offering costs were related to the issuance of Class A common stock and charged to stockholders’ equity and approximately $0.4 million of the offering costs were related to the warrant liabilities and charged to the condensed statement of operations.

Marketable Securities Held in Trust Account

At June 30, 2021, substantially all of the assets held in the Trust Account were held in money market funds which invest in United States Treasury securities.Through June 30, 2021, the Company has not withdrawn any monies from the Trust Account.

Class A Common Stock Subject to Possible Redemption

The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC 480. Shares of Class A common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s Class A common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at June 30, 2021, Class A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet.

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2021 and December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception.

On March 27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) into law. The CARES Act includes several significant business tax provisions that, among other things, would eliminate the taxable income limit for certain net operating losses (“NOL”) and allow businesses to carry back NOLs arising in 2018, 2019 and 2020 to the five prior years, suspend the excess business loss rules, accelerate refunds of previously generated corporate alternative minimum tax credits, generally loosen the business interest limitation under section 163(j) of the Internal Revenue Code of 1986, as amended, from 30 percent to 50 percent among other technical corrections included in the Tax Cuts and Jobs Act tax provisions. The Company does not believe that the CARES Act will have a significant impact on Company's financial position or statement of operations.

Net Loss per Share

Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Shares of common stock subject to possible redemption at June 30, 2021, which are not currently redeemable and are not redeemable at fair value, have been excluded from the calculation of basic net loss per common share since such shares, if redeemed, only participate in their pro rata share of the Trust Account earnings. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the private placement to purchase an aggregate of 15,823,333 shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. As a result, diluted net loss per common share is the same as basic net loss per common share for the periods presented.

The Company’s statement of operations includes a presentation of net earnings (loss) per share for common shares subject to possible redemption and applies the two-class method in calculating net earnings (loss) per share. Net earnings per common share, basic and diluted, for Class A redeemable common stock is calculated by dividing the allocable interest income earned on the Trust Account, net of applicable franchise and income taxes, by the weighted average number of Class A common stock subject to possible redemption outstanding since original issuance. Net loss per share, basic and diluted, for Class A and Class B non-redeemable common stock is calculated by dividing the net loss, adjusted for income attributable to Class A redeemable common stock, by the weighted average number of Class A and Class B non-redeemable common stock outstanding for the period. Class B non-redeemable common stock includes the Founder Shares as these shares do not have any redemption features and do not participate in the income earned on the Trust Account.

The following table reflects the calculation of basic and diluted net earnings (loss) per common share (in dollars, except per share amounts):

    

    

Six Months 

Three Months Ended

Ended 

June 30, 

June 30, 

2021

2021

Class A Common Stock subject to possible redemption

Numerator: Earnings attributable to Class A Common Stock subject to possible redemption

Unrealized gain on marketable securities held in Trust Account

$

4,929

$

25,280

Net earnings attributable to Class A Common Stock subject to possible redemption

$

4,929

$

25,280

Denominator: Weighted average Class A Common Stock subject to possible redemption

Basic and diluted weighted average shares outstanding, Class A Common Stock subject to possible redemption

28,659,098

28,579,419

Basic and diluted net earnings per share, Class A Common Stock subject to possible redemption

$

0.00

$

0.00

Non-Redeemable Class A and Class B Common Stock

Numerator: Net loss minus net earnings

Net loss

$

(4,191,105)

$

(2,623,732)

Less: Net earnings attributable to Class A Common Stock subject to possible redemption

 

(4,929)

 

(25,280)

Non-redeemable net loss

$

(4,196,034)

(2,649,012)

Denominator: Weighted average Non-Redeemable Class A and Class B Common Stock

Basic and diluted weighted average shares outstanding, Non-Redeemable Class A and Class B Common Stock

10,153,402

9,694,261

Basic and diluted net loss per share, Non-Redeemable Class A and Class B Common Stock

$

(0.41)

(0.27)

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.

Fair Value of Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurement” (“ASC 820”), approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature.

Warrants Exercisable for Class A Common Stock

The Company accounted for the 15,823,333 warrants issued in connection with the Initial Public Offering and the Private Placement Warrants (collectively, the “Warrants”) as either equity-classified or liability-classified instruments based on an assessment of the Warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the company’s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s condensed financial statements.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2
INITIAL PUBLIC OFFERING
6 Months Ended
Jun. 30, 2021
INITIAL PUBLIC OFFERING  
INITIAL PUBLIC OFFERING

NOTE 3. INITIAL PUBLIC OFFERING

On January 28, 2021, pursuant to the Initial Public Offering, the Company sold 31,050,000 Units, which includes the full exercise by the underwriter of its over-allotment option in the amount of 4,050,000 Units, at a price of $10.00 per Unit. Each Unit consists of one share of Class A common stock and one-third of one (each whole warrant, a “Public Warrant”). Each whole Public Warrant entitles the holder to purchase one share of Class A common stock at an exercise price of $11.50 per share, subject to adjustment (see Note 8).

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
PRIVATE PLACEMENT
6 Months Ended
Jun. 30, 2021
PRIVATE PLACEMENT  
PRIVATE PLACEMENT

NOTE 4. PRIVATE PLACEMENT

Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 5,473,333 Private Placement Warrants, at a price of $1.50 per Private Placement Warrant, for an aggregate purchase price of $8,210,000 in a private placement. Each Private Placement Warrant is exercisable to purchase one share of Class A common stock at an exercise price of $11.50 per share. $6,210,000 of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination by January 28, 2023 or during any Extension Period, the proceeds of the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. There will be no redemption rights or liquidating distributions from the Trust Account with respect to the Private Placement Warrants.

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
RELATED PARTY TRANSACTIONS
6 Months Ended
Jun. 30, 2021
RELATED PARTY TRANSACTIONS  
RELATED PARTY TRANSACTIONS

NOTE 5. RELATED PARTY TRANSACTIONS

Founder Shares

On October 29, 2020, the Sponsor purchased 6,468,750 Founder Shares (as defined below) for an aggregate purchase price of $25,000. On January 25, 2021, the Company effected a stock dividend of 1,293,750 shares of Class B common stock to holders of Class B common stock on a pro rata basis based on their holdings, resulting in the Company’s initial stockholders holding an aggregate of 7,762,500 Founder Shares.

The initial stockholders have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Class B common stock or Class A common stock received upon conversion thereof (together, “Founder Shares”) until the earlier of: (A) one year after the completion of a Business Combination; and (B) subsequent to a Business Combination (x) if the last reported sale price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, rights issuances, consolidations, reorganizations, recapitalizations and other similar transactions) for any 20 trading days within any 30-trading day period commencing at least 150 days after a Business Combination or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction that results in all of the Company’s public stockholders having the right to exchange their shares of common stock for cash, securities or other property.

Promissory Note — Related Party

On October 29, 2020, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the “Promissory Note”). The Promissory Note was non-interest bearing and payable on the earlier of December 31, 2021 or the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $300,000 remained outstanding at the closing of the Initial Public Offering on January 28, 2021. On February 2, 2021, the Company repaid the Promissory Note in full.

Administrative Services Agreement

The Company agreed, commencing on January 26, 2021 through the earlier of the Company’s consummation of a Business Combination and its liquidation, to pay an affiliate of the Sponsor a total of $10,000 per month for office space, administrative and support services.

Related Party Loans

In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working

Capital Loans”). Such Working Capital Loans would be evidenced by promissory notes. The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender's discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $1.50 per warrant. Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2
COMMITMENTS
6 Months Ended
Jun. 30, 2021
COMMITMENTS  
COMMITMENTS

NOTE 6. COMMITMENTS

Registration Rights

The holders of the Founder Shares, Private Placement Warrants and any warrants that may be issued on conversion of Working Capital Loans (and any Class A common stock issuable upon the exercise of the Private Placement Warrants or warrants issued upon conversion of the Working Capital Loans and upon conversion of the Founder Shares) will be entitled to registration rights pursuant to a registration rights agreement to be signed prior to or on the effective date of the Initial Public Offering requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to the Company’s Class A common stock). The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until termination of the applicable lock-up period. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The underwriters are entitled to a deferred fee of $0.35 per Unit, or $10,867,500 in the aggregate. The deferred fee will be waived by the underwriters in the event that the Company does not complete a Business Combination, subject to the terms of the underwriting agreement by January 28, 2023.

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS' EQUITY
6 Months Ended
Jun. 30, 2021
STOCKHOLDERS' EQUITY  
STOCKHOLDERS' EQUITY

NOTE 7. STOCKHOLDERS’ EQUITY

Preferred Stock — The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 per share. The Company’s board of directors is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. The board of directors is able to, without stockholder approval, issue shares of preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of the common stock and could have anti-takeover effects. At June 30, 2021, there were no shares of preferred stock issued or outstanding.

Common Stock

Class A Common Stock — The Company is authorized to issue 400,000,000 shares of Class A common stock with a par value of $0.0001 per share. Holders of Class A common stock are entitled to one vote for each share. At June 30, 2021, there were 2,809,902 shares of Class A common stock issued and outstanding, excluding 28,240,098 shares of Class A common stock subject to possible redemption.

Class B Common Stock —The Company is authorized to issue 40,000,000 shares of Class B common stock with a par value of $0.0001 per share. Holders of Class B common stock are entitled to one vote for each share. At June 30, 2021, there were 7,762,500 shares of Class B common stock issued and outstanding.

Holders of Class B common stock have the right to elect all of the Company’s directors prior to a Business Combination. Holders of Class A common stock and Class B common stock will vote together as a single class on all other matters submitted to a vote of stockholders except as required by law.

The Class B common stock will automatically convert into Class A common stock at the time of the completion of a Business Combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts issued in the Initial Public

Offering and related to the closing of a Business Combination, the ratio at which Founder Shares will convert into Class A common stock will be adjusted (subject to waiver by holders of a majority of the Class B common stock) so that the number of shares of Class A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, on an as-converted basis, 20% of the sum of the common stock issued and outstanding upon completion of the Initial Public Offering plus the number of shares of Class A common stock and equity-linked securities issued or deemed issued in connection with a Business Combination, excluding any shares of Class A common stock or equity-linked securities issued, or to be issued, to any seller in a Business Combination.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
WARRANTS
6 Months Ended
Jun. 30, 2021
WARRANTS  
WARRANTS

NOTE 8. WARRANTS

Warrants — Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants and only whole warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b) 12 months after the closing of the Initial Public Offering. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.

If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement governing the Warrants (the “Warrant Agreement”). The exercise price and number of shares of Class A common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization, merger or consolidation. However except as described below, the warrants will not be adjusted for issuances of Class A common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of the warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution form the Company’s assets held outside the Trust Account with respect to such warrants. Accordingly, the warrants may expire worthless.

In addition, if (x) the Company issues additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing of the Company’s initial Business Combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by our board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any founder shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the Company’s initial Business Combination on the date of the completion of the Company’s initial Business Combination (net of redemptions), and (z) the volume weighted average trading price of shares of the Company’s Class A common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummate a Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price described below under “Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $18.00” and “Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described below under “Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $10.00” will be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price.

The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act covering the issuance of the shares of Class A common stock issuable upon exercise of the Public Warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration or a valid exemption from registration is available. No Public Warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their Public Warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption from registration is available.

The Company has agreed that as soon as practicable, but in no event later than 15 business days, after the closing of a Business Combination, it will use its commercially reasonable efforts to file with the SEC a registration statement registering the issuance, under the Securities Act, of the Class A common stock issuable upon exercise of the Public Warrants. The Company will use its commercially reasonable efforts to cause the same to become effective within 60 business days after the closing of a Business Combination and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the Public Warrants in accordance with the provisions of the Warrant Agreement. Notwithstanding the above, if the Class A common stock is, at

the time of any exercise of a Public Warrant, not listed on a national securities exchange such that they do not satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their Public Warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.

Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $18.00. Once the Public Warrants become exercisable, the Company may redeem the Public Warrants:

in whole and not in part;
at a price of $0.01 per Public Warrant;
upon not less than 30 days' prior written notice of redemption to each warrant holder; and
if, and only if, the last reported sale price of shares of the Class A common stock for any 20 trading days within a 30 -trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the “Reference Value”) equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant).

Redemption of warrants when the price per share of the Company’s Class A common stock equals or exceeds $10.00. Once the Public Warrants become exercisable, the Company may redeem the Public Warrants:

in whole and not in part;
at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the “fair market value” of the Class A common stock;
if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted); and
if the Reference Value is less than $18.00 per share (as adjusted), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants.

If and when the Public Warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws.

The Private Placement Warrants are identical to the Public Warrants underlying the Units that were sold in the Initial Public Offering, except that the Private Placement Warrants and the Class A common stock issuable upon the exercise of the Private Placement Warrants are not transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants are exercisable on a cashless basis and are non-redeemable, except as described above, so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants are redeemable by the Company and are exercisable by such holders on the same basis as the Public Warrants.

The Warrants are not considered to be indexed to the Company’s stock price. In accordance with FASB ASC 815, the warrants were classified as a liability in the total amount of $11.6 million at January 28, 2021. In addition, the warrants must be valued every reporting period and adjusted to market with the increase or decrease being adjusted through earnings. As of June 30, 2021 the fair value of the warrant liability was $13.5 million.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
FAIR VALUE MEASUREMENTS
6 Months Ended
Jun. 30, 2021
FAIR VALUE MEASUREMENTS  
FAIR VALUE MEASUREMENTS

NOTE 9. FAIR VALUE MEASUREMENTS

The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually.

The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:

Level 1:Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.

Level 1 assets and liabilities at fair value is comprised of Cash, Cash held in the Trust Account and Public Warrants. The company has no other Level 1 assets or liabilities at fair value and no Level 2 assets or liabilities at fair value at June 30, 2021 and December 31, 2020. The Company has warrants exercisable for Class A common stock with a fair value of $13,534,768 and $0 as of June 30, 2021 and December 31, 2020, respectively. The Private Placement Warrants are classified as Level 3 based on a valuation model that utilizes both observable and unobservable inputs. Observable inputs include market prices of warrants issued by other special purpose acquisition companies and unobservable inputs include model adjustments for valuation uncertainty pertaining to the probability of the Company consummating a Business Combination. There were no transfers into or out of Level 3 within the fair value hierarchy during the three and six month periods ended June 30, 2021. The following table provides a summary of the changes in fair value of the Company’s Level 3 assets and liabilities for the six months ended June 30, 2021.

Private Placement Warrants

Exercisable for

Class A common

    

stock

Balance December 31, 2020

$

Initial fair value

 

4,050,266

Changes in fair value of warrant liability

(711,533)

Fair Value at March 31, 2021

3,338,733

Change in fair value of warrant liability

 

1,342,979

Fair Value at June 30, 2021

$

4,681,712

The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at June 30, 2021 and December 31, 2020, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

    

    

June 30, 

    

December 31, 

Description

Level

 

2021

 

2020

Assets:

 

  

 

  

 

  

Marketable securities held in Trust Account

 

1

$

310,534,744

$

Liabilities:

 

  

 

 

  

Public warrants

1

$

8,853,056

$

Private warrants

3

$

4,681,712

$

The Warrants were initially valued using a Monte Carlo simulation model, with the observable assumptions as provided in the table below. Significant increases in the expected stock prices and expected liquidity would result in a significantly higher fair value measurement. Significant increases in either the probability or severity of default of the host instrument would result in a significantly lower fair value measurement. The measurement of the Public Warrants after the detachment of the Public Warrants from the Units is classified as Level 1 due to the use of an observable market quote in an active market. For periods subsequent to the detachment of the

Public Warrants from the Units, the closing price of the Public Warrant was used as the fair value for the Public Warrants as of each relevant date.

    

As of 

    

As of 

 

January 28,

June 30,

 

2021

2021

 

Stock price on valuation date

$

9.76

$

9.71

Exercise price

$

11.50

$

11.50

Term (years)

 

5.93

 

6.09

Expected volatility

 

14.0

%

 

13.3

%

Weighted average risk-free interest rate

 

0.57

%

 

1.05

%

Trials

 

400

 

400

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2
SUBSEQUENT EVENTS
6 Months Ended
Jun. 30, 2021
SUBSEQUENT EVENTS  
SUBSEQUENT EVENTS

NOTE 10. SUBSEQUENT EVENTS

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements.

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended
Jun. 30, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (the “SEC”). Certain information or footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.

The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on April 7, 2021, which contains the audited financial statements and notes thereto. The financial information as of December 31, 2020 is derived from the audited financial statements presented in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The interim results for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any future interim periods.

Emerging Growth Company

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is either not an emerging growth company or an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates

Use of Estimates

The preparation of the condensed financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. Cash equivalents consist of mutual funds. The Company did not have any cash equivalents as of June 30, 2021 and December 31, 2020.

Offering Costs

Offering Costs

Offering costs consist of legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial Public Offering. These costs, together with the upfront underwriting discounts, the deferred underwriting commissions and the financial advisory fee in connection with the Initial Public Offering were charged to stockholders’ equity and warrants exercisable for Class A common stock upon the completion of the Initial Public Offering. Approximately $17.1 million of the offering costs were related to the issuance of Class A common stock and charged to stockholders’ equity and approximately $0.4 million of the offering costs were related to the warrant liabilities and charged to the condensed statement of operations.

Marketable Securities Held in Trust Account

Marketable Securities Held in Trust Account

At June 30, 2021, substantially all of the assets held in the Trust Account were held in money market funds which invest in United States Treasury securities.Through June 30, 2021, the Company has not withdrawn any monies from the Trust Account.

Class A Common Stock Subject to Possible Redemption

Class A Common Stock Subject to Possible Redemption

The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC 480. Shares of Class A common stock subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’ equity. The Company’s Class A common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. Accordingly, at June 30, 2021, Class A common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the stockholders’ equity section of the Company’s balance sheet.

Income Taxes

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statements recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2021 and December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception.

On March 27, 2020, President Trump signed the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) into law. The CARES Act includes several significant business tax provisions that, among other things, would eliminate the taxable income limit for certain net operating losses (“NOL”) and allow businesses to carry back NOLs arising in 2018, 2019 and 2020 to the five prior years, suspend the excess business loss rules, accelerate refunds of previously generated corporate alternative minimum tax credits, generally loosen the business interest limitation under section 163(j) of the Internal Revenue Code of 1986, as amended, from 30 percent to 50 percent among other technical corrections included in the Tax Cuts and Jobs Act tax provisions. The Company does not believe that the CARES Act will have a significant impact on Company's financial position or statement of operations.

Net Income per Share

Net Loss per Share

Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Shares of common stock subject to possible redemption at June 30, 2021, which are not currently redeemable and are not redeemable at fair value, have been excluded from the calculation of basic net loss per common share since such shares, if redeemed, only participate in their pro rata share of the Trust Account earnings. The Company has not considered the effect of the warrants sold in the Initial Public Offering and the private placement to purchase an aggregate of 15,823,333 shares in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. As a result, diluted net loss per common share is the same as basic net loss per common share for the periods presented.

The Company’s statement of operations includes a presentation of net earnings (loss) per share for common shares subject to possible redemption and applies the two-class method in calculating net earnings (loss) per share. Net earnings per common share, basic and diluted, for Class A redeemable common stock is calculated by dividing the allocable interest income earned on the Trust Account, net of applicable franchise and income taxes, by the weighted average number of Class A common stock subject to possible redemption outstanding since original issuance. Net loss per share, basic and diluted, for Class A and Class B non-redeemable common stock is calculated by dividing the net loss, adjusted for income attributable to Class A redeemable common stock, by the weighted average number of Class A and Class B non-redeemable common stock outstanding for the period. Class B non-redeemable common stock includes the Founder Shares as these shares do not have any redemption features and do not participate in the income earned on the Trust Account.

The following table reflects the calculation of basic and diluted net earnings (loss) per common share (in dollars, except per share amounts):

    

    

Six Months 

Three Months Ended

Ended 

June 30, 

June 30, 

2021

2021

Class A Common Stock subject to possible redemption

Numerator: Earnings attributable to Class A Common Stock subject to possible redemption

Unrealized gain on marketable securities held in Trust Account

$

4,929

$

25,280

Net earnings attributable to Class A Common Stock subject to possible redemption

$

4,929

$

25,280

Denominator: Weighted average Class A Common Stock subject to possible redemption

Basic and diluted weighted average shares outstanding, Class A Common Stock subject to possible redemption

28,659,098

28,579,419

Basic and diluted net earnings per share, Class A Common Stock subject to possible redemption

$

0.00

$

0.00

Non-Redeemable Class A and Class B Common Stock

Numerator: Net loss minus net earnings

Net loss

$

(4,191,105)

$

(2,623,732)

Less: Net earnings attributable to Class A Common Stock subject to possible redemption

 

(4,929)

 

(25,280)

Non-redeemable net loss

$

(4,196,034)

(2,649,012)

Denominator: Weighted average Non-Redeemable Class A and Class B Common Stock

Basic and diluted weighted average shares outstanding, Non-Redeemable Class A and Class B Common Stock

10,153,402

9,694,261

Basic and diluted net loss per share, Non-Redeemable Class A and Class B Common Stock

$

(0.41)

(0.27)

Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management believes the Company is not exposed to significant risks on such account.

Fair Value of Financial Instruments

Fair Value of Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurement” (“ASC 820”), approximates the carrying amounts represented in the accompanying condensed balance sheets, primarily due to their short-term nature.

Warrants Exercisable for Class A Common Stock

Warrants Exercisable for Class A Common Stock

The Company accounted for the 15,823,333 warrants issued in connection with the Initial Public Offering and the Private Placement Warrants (collectively, the “Warrants”) as either equity-classified or liability-classified instruments based on an assessment of the Warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the company’s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s condensed financial statements.

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
6 Months Ended
Jun. 30, 2021
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Schedule of basic and diluted income per common share

    

    

Six Months 

Three Months Ended

Ended 

June 30, 

June 30, 

2021

2021

Class A Common Stock subject to possible redemption

Numerator: Earnings attributable to Class A Common Stock subject to possible redemption

Unrealized gain on marketable securities held in Trust Account

$

4,929

$

25,280

Net earnings attributable to Class A Common Stock subject to possible redemption

$

4,929

$

25,280

Denominator: Weighted average Class A Common Stock subject to possible redemption

Basic and diluted weighted average shares outstanding, Class A Common Stock subject to possible redemption

28,659,098

28,579,419

Basic and diluted net earnings per share, Class A Common Stock subject to possible redemption

$

0.00

$

0.00

Non-Redeemable Class A and Class B Common Stock

Numerator: Net loss minus net earnings

Net loss

$

(4,191,105)

$

(2,623,732)

Less: Net earnings attributable to Class A Common Stock subject to possible redemption

 

(4,929)

 

(25,280)

Non-redeemable net loss

$

(4,196,034)

(2,649,012)

Denominator: Weighted average Non-Redeemable Class A and Class B Common Stock

Basic and diluted weighted average shares outstanding, Non-Redeemable Class A and Class B Common Stock

10,153,402

9,694,261

Basic and diluted net loss per share, Non-Redeemable Class A and Class B Common Stock

$

(0.41)

(0.27)

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
FAIR VALUE MEASUREMENTS (Tables)
6 Months Ended
Jun. 30, 2021
FAIR VALUE MEASUREMENTS  
Schedule of change in the fair value of the warrant liabilities

Private Placement Warrants

Exercisable for

Class A common

    

stock

Balance December 31, 2020

$

Initial fair value

 

4,050,266

Changes in fair value of warrant liability

(711,533)

Fair Value at March 31, 2021

3,338,733

Change in fair value of warrant liability

 

1,342,979

Fair Value at June 30, 2021

$

4,681,712

Schedule of Company's assets that are measured at fair value on a recurring basis

    

    

June 30, 

    

December 31, 

Description

Level

 

2021

 

2020

Assets:

 

  

 

  

 

  

Marketable securities held in Trust Account

 

1

$

310,534,744

$

Liabilities:

 

  

 

 

  

Public warrants

1

$

8,853,056

$

Private warrants

3

$

4,681,712

$

Schedule of quantitative information regarding Level 3 fair value measurements inputs

Public Warrants from the Units, the closing price of the Public Warrant was used as the fair value for the Public Warrants as of each relevant date.

    

As of 

    

As of 

 

January 28,

June 30,

 

2021

2021

 

Stock price on valuation date

$

9.76

$

9.71

Exercise price

$

11.50

$

11.50

Term (years)

 

5.93

 

6.09

Expected volatility

 

14.0

%

 

13.3

%

Weighted average risk-free interest rate

 

0.57

%

 

1.05

%

Trials

 

400

 

400

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
ORGANIZATION AND PLANS OF BUSINESS OPERATIONS (Details)
3 Months Ended 6 Months Ended
Jan. 28, 2021
USD ($)
$ / shares
shares
Jan. 25, 2021
shares
Oct. 29, 2020
USD ($)
Mar. 31, 2021
shares
Jun. 30, 2021
USD ($)
item
$ / shares
shares
Dec. 31, 2020
USD ($)
Subsidiary, Sale of Stock [Line Items]            
Issue price per unit | $ / shares         $ 10.00  
Sale of Private Placement Warrants (in shares) | shares         15,823,333  
Proceeds from the sale of Private Placements Warrants         $ 8,210,000  
Transaction Costs $ 17,495,500          
Underwriting fees 6,210,000          
Deferred Offering Costs Noncurrent 10,867,500       10,867,500  
Other offering costs 418,000          
Cash held outside the Trust Account $ 2,300,000       868,722 $ 20,000
WorkingCapital         1,293,227  
Payments for investment of cash in Trust Account         $ 310,500,000  
Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent)         100.00%  
Threshold minimum aggregate fair market value as a percentage of the net assets held in the Trust Account         80.00%  
Redemption of shares calculated based on business days prior to consummation of business combination (in days) | item         2  
Condition for future business combination threshold Net Tangible Assets         $ 5,000,001  
Number of days to redeem shares if business combination is not completed by specified date         10 days  
Maximum interest to pay dissolution expenses         $ 100,000  
Private Placement Warrants            
Subsidiary, Sale of Stock [Line Items]            
Number of units sold | shares       5,473,333    
Initial Public Offering            
Subsidiary, Sale of Stock [Line Items]            
Number of units sold | shares 31,050,000 31,050,000        
Issue price per unit | $ / shares $ 10.00          
Proceeds from issuance initial public offering $ 310,500,000          
Payments for investment of cash in Trust Account $ 310,500,000          
Private Placement | Private Placement Warrants            
Subsidiary, Sale of Stock [Line Items]            
Sale of Private Placement Warrants (in shares) | shares 5,473,333       5,473,333  
Price of warrant | $ / shares $ 1.50       $ 1.50  
Proceeds from the sale of Private Placements Warrants $ 8,210,000       $ 8,210,000  
Over-allotment option            
Subsidiary, Sale of Stock [Line Items]            
Number of units sold | shares 4,050,000          
Issue price per unit | $ / shares $ 10.00          
Promissory Note with Related Party            
Subsidiary, Sale of Stock [Line Items]            
MaximumBorrowingCapacityOfRelatedPartyPromissoryNote     $ 300,000      
Class B Common Stock | Sponsor | Founder Shares            
Subsidiary, Sale of Stock [Line Items]            
Aggregate purchase price     $ 25,000      
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)
6 Months Ended
Jun. 30, 2021
Dec. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES    
Unrecognized tax benefits $ 0  
Unrecognized tax benefits accrued for interest and penalties   $ 0
Federal Depository Insurance Coverage $ 250,000  
Number of warrants to purchase shares issued 15,823,333  
Offering costs charged to shareholders' equity $ 17,100,000  
Offering costs related to warrant liabilities $ 400,000  
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Net Income per Common Share (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2021
Numerator: Earnings attributable to Class A Common Stock subject to possible redemption      
Unrealized gain on marketable securities held in Trust Account $ 4,929   $ 25,280
Net earnings attributable to Class A Common Stock subject to possible redemption 4,929   25,280
Numerator: Net loss minus net earnings      
Net income (loss) (4,191,105) $ 1,567,374 (2,623,732)
Less: Net earnings attributable to Class A Common Stock subject to possible redemption $ 4,929   $ 25,280
Class A Common Stock Subject to Redemption      
Denominator: Weighted average Class A Common Stock subject to possible redemption      
Weighted average shares outstanding, basic and diluted 28,659,098   28,579,419
Basic and diluted net loss per share $ 0.00   $ 0.00
Non redeemable Class A and Class B Common Stock      
Numerator: Earnings attributable to Class A Common Stock subject to possible redemption      
Net earnings attributable to Class A Common Stock subject to possible redemption $ (4,929)   $ (25,280)
Numerator: Net loss minus net earnings      
Net income (loss) (4,191,105)   (2,623,732)
Less: Net earnings attributable to Class A Common Stock subject to possible redemption (4,929)   (25,280)
Non-redeemable net loss $ (4,196,034)   $ (2,649,012)
Denominator: Weighted average Class A Common Stock subject to possible redemption      
Weighted average shares outstanding, basic and diluted 10,153,402   9,694,261
Basic and diluted net loss per share $ (0.41)   $ (0.27)
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restatement of Previously Issued Financial Statement as of January 28, 2021 (Details) - USD ($)
Jun. 30, 2021
Jan. 28, 2021
Dec. 31, 2020
Balance sheet as of January 28, 2021 (audited)      
Warrant Liability $ 13,534,768 $ 11,600,000 $ 0
Total Liabilities 24,544,286   183,912
Additional Paid-in Capital 7,627,684   24,224
Accumulated Deficit (2,628,731)   $ (5,000)
Class A Common Stock Subject to Redemption      
Balance sheet as of January 28, 2021 (audited)      
Common Stock Subject to Possible Redemption $ 282,425,690    
Number of shares subject to redemption 28,240,098   0
Class A Common Stock Not Subject to Redemption      
Balance sheet as of January 28, 2021 (audited)      
Common stock $ 281    
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
INITIAL PUBLIC OFFERING (Details) - $ / shares
Jan. 28, 2021
Jan. 25, 2021
Jun. 30, 2021
Subsidiary, Sale of Stock [Line Items]      
Issue price per unit     $ 10.00
Initial Public Offering      
Subsidiary, Sale of Stock [Line Items]      
Number of units sold 31,050,000 31,050,000  
Issue price per unit $ 10.00    
Initial Public Offering | Public Warrants      
Subsidiary, Sale of Stock [Line Items]      
Number of shares in a unit 1    
Number of warrants in a unit 0.33    
Number of shares issuable per warrant 1    
Exercise price of warrants $ 11.50    
Over-allotment option      
Subsidiary, Sale of Stock [Line Items]      
Number of units sold 4,050,000    
Issue price per unit $ 10.00    
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
PRIVATE PLACEMENT (Details) - USD ($)
6 Months Ended
Jan. 28, 2021
Jun. 30, 2021
Subsidiary, Sale of Stock [Line Items]    
Number of warrants to purchase shares issued   15,823,333
Aggregate purchase price   $ 8,210,000
Amount held in the trust account from private placement warrants issuance proceeds   $ 6,210,000
Private Placement | Private Placement Warrants    
Subsidiary, Sale of Stock [Line Items]    
Number of warrants to purchase shares issued 5,473,333 5,473,333
Price of warrants $ 1.50 $ 1.50
Aggregate purchase price $ 8,210,000 $ 8,210,000
Number of shares per warrant   1
Exercise price of warrant   $ 11.50
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2
RELATED PARTY TRANSACTIONS - Founder Shares (Details) - Founder Shares - Sponsor - Class B Common Stock
6 Months Ended
Jan. 25, 2021
shares
Oct. 29, 2020
USD ($)
shares
Jun. 30, 2021
item
$ / shares
Related Party Transaction [Line Items]      
Number of shares issued   6,468,750  
Aggregate purchase price | $   $ 25,000  
Share dividend 1,293,750    
Aggregate number of shares owned 7,762,500    
Restrictions on transfer period of time after business combination completion     1 year
Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share) | $ / shares     $ 12.00
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | item     20
Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | item     30
Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences     150 days
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
RELATED PARTY TRANSACTIONS - Additional Information (Details) - USD ($)
6 Months Ended
Feb. 02, 2021
Jun. 30, 2021
Oct. 29, 2020
Related Party Transaction [Line Items]      
Repayment of promissory note - related party   $ 300,000  
Promissory Note with Related Party      
Related Party Transaction [Line Items]      
Maximum borrowing capacity of related party promissory note     $ 300,000
Repayment of promissory note - related party $ 300,000    
Administrative Support Agreement      
Related Party Transaction [Line Items]      
Expenses per month   10,000  
Related Party Loans      
Related Party Transaction [Line Items]      
Loan conversion agreement warrant   $ 1,500,000  
Related Party Loans | Working capital loans warrant      
Related Party Transaction [Line Items]      
Price of warrant   $ 1.50  
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
COMMITMENTS (Details)
Jan. 28, 2021
USD ($)
$ / shares
shares
Jun. 30, 2021
USD ($)
item
$ / shares
Subsidiary, Sale of Stock [Line Items]    
Number of demands securities are entitled to | item   3
Issue price per unit   $ 10.00
Deferred fee per unit   $ 0.35
Deferred Offering Costs Noncurrent | $ $ 10,867,500 $ 10,867,500
Over-allotment option    
Subsidiary, Sale of Stock [Line Items]    
Number of units sold | shares 4,050,000  
Issue price per unit $ 10.00  
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS' EQUITY - Preferred Stock Shares (Details) - $ / shares
Jun. 30, 2021
Dec. 31, 2020
STOCKHOLDERS' EQUITY    
Preferred shares, shares authorized 1,000,000 1,000,000
Preferred stock, par value, (per share) $ 0.0001 $ 0.0001
Preferred shares, shares issued 0 0
Preferred shares, shares outstanding 0 0
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS' EQUITY - Common Stock Shares (Details)
6 Months Ended
Jun. 30, 2021
Vote
$ / shares
shares
Dec. 31, 2020
$ / shares
shares
Class of Stock [Line Items]    
Class B common stock conversion ratio to Class B 1  
Class A Common Stock Subject to Redemption    
Class of Stock [Line Items]    
Class A common stock subject to possible redemption, issued (in shares) 28,240,098 0
Class A common stock subject to possible redemption, outstanding (in shares) 28,240,098 0
Class A Common Stock Not Subject to Redemption    
Class of Stock [Line Items]    
Common shares, shares authorized (in shares) 400,000,000 400,000,000
Common shares, par value (in dollars per share) | $ / shares $ 0.0001 $ 0.0001
Common shares, votes per share | Vote 1  
Common shares, shares issued (in shares) 2,809,902 0
Common shares, shares outstanding (in shares) 2,809,902 0
Class B Common Stock    
Class of Stock [Line Items]    
Common shares, shares authorized (in shares) 40,000,000 40,000,000
Common shares, par value (in dollars per share) | $ / shares $ 0.0001 $ 0.0001
Common shares, votes per share | Vote 1  
Common shares, shares issued (in shares) 7,762,500 7,762,500
Common shares, shares outstanding (in shares) 7,762,500 7,762,500
Ratio to be applied to the stock in the conversion 20  
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
WARRANTS (Details)
6 Months Ended
Jun. 30, 2021
USD ($)
item
$ / shares
Jan. 28, 2021
USD ($)
Dec. 31, 2020
USD ($)
Class of Warrant or Right [Line Items]      
Fair value of warrant liabilities | $ $ 13,534,768 $ 11,600,000 $ 0
Public Warrants      
Class of Warrant or Right [Line Items]      
Public Warrants exercisable term after the completion of a business combination 30 days    
Public Warrants exercisable term from the closing of the initial public offering 12 months    
Public Warrants expiration term 5 years    
Threshold issue price per share $ 9.20    
Adjustment of exercise price of warrants based on market value and newly issued price (as a percent) 115.00%    
Adjustment of redemption price of stock based on market value and newly issued price (as a percent) 180.00%    
Maximum period after business combination in which to file registration statement 15 days    
Period of time within which registration statement is expected to become effective 60 days    
Public Warrants | Class A Common Stock      
Class of Warrant or Right [Line Items]      
Threshold issue price per share $ 9.20    
Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant 60.00%    
Trading period after business combination used to measure dilution of warrant | item 20    
Public Warrants | Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00      
Class of Warrant or Right [Line Items]      
Stock price trigger for redemption of public warrants (in dollars per share) $ 18.00    
Redemption price per warrant (in dollars per share) $ 0.01    
Threshold trading days for redemption of public warrants | item 20    
Threshold consecutive trading days for redemption of public warrants | item 30    
Minimum threshold written notice period for redemption of public warrants 30 days    
Public Warrants | Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $10.00      
Class of Warrant or Right [Line Items]      
Stock price trigger for redemption of public warrants (in dollars per share) $ 10.00    
Redemption price per warrant (in dollars per share) $ 0.10    
Minimum threshold written notice period for redemption of public warrants 30 days    
Private Placement Warrants      
Class of Warrant or Right [Line Items]      
Restrictions on transfer period of time after business combination completion 30 days    
Public And Private Placement Warrants [Member]      
Class of Warrant or Right [Line Items]      
Fair value of warrant liabilities | $ $ 13,500,000    
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
FAIR VALUE MEASUREMENTS (Details) - USD ($)
Jun. 30, 2021
Jan. 28, 2021
Dec. 31, 2020
Assets:      
Marketable securities held in Trust Account $ 310,534,744    
Liabilities:      
Warrant liability 13,534,768 $ 11,600,000 $ 0
Level 1 | Recurring      
Assets:      
Marketable securities held in Trust Account 310,534,744    
Level 1 | Recurring | Public Warrants      
Liabilities:      
Warrant liability 8,853,056    
Level 3 | Recurring | Private Placement Warrants      
Liabilities:      
Warrant liability $ 4,681,712    
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.2
FAIR VALUE MEASUREMENTS - Level 3 Fair Value Measurements Inputs (Details)
Jun. 30, 2021
Jan. 28, 2021
Stock price on valuation date    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability, Measurement Input 9.71 9.76
Exercise price    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability, Measurement Input 11.50 11.50
Term (years)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability, Measurement Input 6.09 5.93
Expected volatility    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability, Measurement Input 13.3 14.0
Weighted average risk-free interest rate    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability, Measurement Input 1.05 0.57
Trials    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative Liability, Measurement Input 400 400
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.2
FAIR VALUE MEASUREMENTS - Change in the Fair Value of the Warrant Liabilities (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2021
Jan. 28, 2021
Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]          
Warrant liability $ 13,534,768   $ 13,534,768 $ 11,600,000 $ 0
Transfers into Level 3 0        
Transfers out of Level 3 0        
Level 3          
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]          
Balance December 31, 2020 3,338,733        
Initial fair value     4,050,266    
Change in fair value of warrant liability   $ (711,533) 1,342,979    
Fair Value at June 30, 2021 $ 4,681,712 $ 3,338,733 $ 4,681,712    
EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 49 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 85 255 1 false 32 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Balance Sheets Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Statement of Operations Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations Condensed Statement of Operations Statements 4 false false R5.htm 00205 - Statement - Condensed Statement of Operations (Parenthetical) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperationsParenthetical Condensed Statement of Operations (Parenthetical) Statements 5 false false R6.htm 00300 - Statement - Condensed Statement of Changes in Stockholders' Equity Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity Condensed Statement of Changes in Stockholders' Equity Statements 6 false false R7.htm 00305 - Statement - Condensed Statement of Changes in Stockholders' Equity (Parenthetical) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquityParenthetical Condensed Statement of Changes in Stockholders' Equity (Parenthetical) Statements 7 false false R8.htm 00400 - Statement - Condensed Statement of Cash Flows Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows Condensed Statement of Cash Flows Statements 8 false false R9.htm 10101 - Disclosure - ORGANIZATION AND PLANS OF BUSINESS OPERATIONS Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperations ORGANIZATION AND PLANS OF BUSINESS OPERATIONS Notes 9 false false R10.htm 10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 10301 - Disclosure - INITIAL PUBLIC OFFERING Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOffering INITIAL PUBLIC OFFERING Notes 11 false false R12.htm 10401 - Disclosure - PRIVATE PLACEMENT Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacement PRIVATE PLACEMENT Notes 12 false false R13.htm 10501 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 13 false false R14.htm 10601 - Disclosure - COMMITMENTS Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitments COMMITMENTS Notes 14 false false R15.htm 10701 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquity STOCKHOLDERS' EQUITY Notes 15 false false R16.htm 10801 - Disclosure - WARRANTS Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrants WARRANTS Notes 16 false false R17.htm 10901 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurements FAIR VALUE MEASUREMENTS Notes 17 false false R18.htm 11001 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSubsequentEvents SUBSEQUENT EVENTS Notes 18 false false R19.htm 20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 19 false false R20.htm 30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPolicies 20 false false R21.htm 30903 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurements 21 false false R22.htm 40101 - Disclosure - ORGANIZATION AND PLANS OF BUSINESS OPERATIONS (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails ORGANIZATION AND PLANS OF BUSINESS OPERATIONS (Details) Details http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperations 22 false false R23.htm 40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Net Income per Common Share (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Net Income per Common Share (Details) Details 24 false false R25.htm 40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restatement of Previously Issued Financial Statement as of January 28, 2021 (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestatementOfPreviouslyIssuedFinancialStatementAsOfJanuary282021Details SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restatement of Previously Issued Financial Statement as of January 28, 2021 (Details) Details 25 false false R26.htm 40301 - Disclosure - INITIAL PUBLIC OFFERING (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails INITIAL PUBLIC OFFERING (Details) Details http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOffering 26 false false R27.htm 40401 - Disclosure - PRIVATE PLACEMENT (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails PRIVATE PLACEMENT (Details) Details http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacement 27 false false R28.htm 40501 - Disclosure - RELATED PARTY TRANSACTIONS - Founder Shares (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails RELATED PARTY TRANSACTIONS - Founder Shares (Details) Details 28 false false R29.htm 40502 - Disclosure - RELATED PARTY TRANSACTIONS - Additional Information (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails RELATED PARTY TRANSACTIONS - Additional Information (Details) Details 29 false false R30.htm 40601 - Disclosure - COMMITMENTS (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsDetails COMMITMENTS (Details) Details http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitments 30 false false R31.htm 40701 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock Shares (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityPreferredStockSharesDetails STOCKHOLDERS' EQUITY - Preferred Stock Shares (Details) Details 31 false false R32.htm 40702 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock Shares (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityCommonStockSharesDetails STOCKHOLDERS' EQUITY - Common Stock Shares (Details) Details 32 false false R33.htm 40801 - Disclosure - WARRANTS (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails WARRANTS (Details) Details http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrants 33 false false R34.htm 40901 - Disclosure - FAIR VALUE MEASUREMENTS (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails FAIR VALUE MEASUREMENTS (Details) Details http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsTables 34 false false R35.htm 40902 - Disclosure - FAIR VALUE MEASUREMENTS - Level 3 Fair Value Measurements Inputs (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsLevel3FairValueMeasurementsInputsDetails FAIR VALUE MEASUREMENTS - Level 3 Fair Value Measurements Inputs (Details) Details 35 false false R36.htm 40903 - Disclosure - FAIR VALUE MEASUREMENTS - Change in the Fair Value of the Warrant Liabilities (Details) Sheet http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfWarrantLiabilitiesDetails FAIR VALUE MEASUREMENTS - Change in the Fair Value of the Warrant Liabilities (Details) Details 36 false false All Reports Book All Reports ssaau-20210630x10q.htm ssaau-20210630.xsd ssaau-20210630_cal.xml ssaau-20210630_def.xml ssaau-20210630_lab.xml ssaau-20210630_pre.xml ssaau-20210630xex31d1.htm ssaau-20210630xex31d2.htm ssaau-20210630xex32d1.htm ssaau-20210630xex32d2.htm http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true JSON 54 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ssaau-20210630x10q.htm": { "axisCustom": 0, "axisStandard": 10, "contextCount": 85, "dts": { "calculationLink": { "local": [ "ssaau-20210630_cal.xml" ] }, "definitionLink": { "local": [ "ssaau-20210630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "ssaau-20210630x10q.htm" ] }, "labelLink": { "local": [ "ssaau-20210630_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "ssaau-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "ssaau-20210630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 295, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 15, "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630": 1, "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 21 }, "keyCustom": 69, "keyStandard": 186, "memberCustom": 17, "memberStandard": 15, "nsprefix": "ssaau", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "ssaau:InitialPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - INITIAL PUBLIC OFFERING", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOffering", "shortName": "INITIAL PUBLIC OFFERING", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "ssaau:InitialPublicOfferingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "ssaau:PrivatePlacementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - PRIVATE PLACEMENT", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacement", "shortName": "PRIVATE PLACEMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "ssaau:PrivatePlacementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - COMMITMENTS", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitments", "shortName": "COMMITMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquity", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "ssaau:WarrantLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - WARRANTS", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrants", "shortName": "WARRANTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "ssaau:WarrantLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurements", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - SUBSEQUENT EVENTS", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_Fk7CpAVK10uwm4jOA1BTUA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Condensed Balance Sheets", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "shortName": "Condensed Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_12_31_2020_z-bIkb8tr0uxqGWeUlsdCA", "decimals": "0", "lang": null, "name": "us-gaap:DeferredCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_Fk7CpAVK10uwm4jOA1BTUA", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_7R7M07aoukakuhDQvanGmw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - ORGANIZATION AND PLANS OF BUSINESS OPERATIONS (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "shortName": "ORGANIZATION AND PLANS OF BUSINESS OPERATIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_1_28_2021_bM89Li3MMkCri-mQISx0tg", "decimals": "0", "lang": null, "name": "ssaau:TransactionCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_Fk7CpAVK10uwm4jOA1BTUA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_Fk7CpAVK10uwm4jOA1BTUA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_PPVafkN1t0GODQRSEJxskQ", "decimals": "0", "first": true, "lang": null, "name": "ssaau:UnrealizedGainLossOnInvestment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Net Income per Common Share (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Net Income per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_PPVafkN1t0GODQRSEJxskQ", "decimals": "0", "first": true, "lang": null, "name": "ssaau:UnrealizedGainLossOnInvestment", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_Fk7CpAVK10uwm4jOA1BTUA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares", "reportCount": 1, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restatement of Previously Issued Financial Statement as of January 28, 2021 (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestatementOfPreviouslyIssuedFinancialStatementAsOfJanuary282021Details", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restatement of Previously Issued Financial Statement as of January 28, 2021 (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R26": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_Fk7CpAVK10uwm4jOA1BTUA", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_7R7M07aoukakuhDQvanGmw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - INITIAL PUBLIC OFFERING (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "shortName": "INITIAL PUBLIC OFFERING (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ssaau:InitialPublicOfferingTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_28_2021_To_1_28_2021_us-gaap_ClassOfWarrantOrRightAxis_ssaau_PublicWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_BeQ7PX6YSkyTTW8a5NDlpw", "decimals": "INF", "lang": null, "name": "ssaau:NumberOfSharesIssuedPerUnit", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_6i4NST_38UeUN04BrV1QVA", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_Fk7CpAVK10uwm4jOA1BTUA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Unit_Standard_shares_6i4NST_38UeUN04BrV1QVA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - PRIVATE PLACEMENT (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "shortName": "PRIVATE PLACEMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ssaau:PrivatePlacementTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": "0", "lang": null, "name": "ssaau:AmountHeldInTrustAccountFromPrivatePlacementWarrantsIssuance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_10_29_2020_To_10_29_2020_us-gaap_RelatedPartyTransactionAxis_ssaau_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ssaau_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_ZYljuKG0kk2w2CAvVjwWIw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_6i4NST_38UeUN04BrV1QVA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - RELATED PARTY TRANSACTIONS - Founder Shares (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "shortName": "RELATED PARTY TRANSACTIONS - Founder Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_10_29_2020_To_10_29_2020_us-gaap_RelatedPartyTransactionAxis_ssaau_FounderSharesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ssaau_SponsorMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_ZYljuKG0kk2w2CAvVjwWIw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_6i4NST_38UeUN04BrV1QVA", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfRelatedPartyDebt", "reportCount": 1, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - RELATED PARTY TRANSACTIONS - Additional Information (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "RELATED PARTY TRANSACTIONS - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_10_29_2020_us-gaap_RelatedPartyTransactionAxis_ssaau_PromissoryNoteWithRelatedPartyMember_wxKApUykhEi0VxcLOCt8nQ", "decimals": "0", "lang": null, "name": "ssaau:MaximumBorrowingCapacityOfRelatedPartyPromissoryNote", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_Fk7CpAVK10uwm4jOA1BTUA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_7R7M07aoukakuhDQvanGmw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - Condensed Balance Sheets (Parenthetical)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical", "shortName": "Condensed Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_Fk7CpAVK10uwm4jOA1BTUA", "decimals": "INF", "first": true, "lang": null, "name": "ssaau:FounderSharesAndWarrantsDemands", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_Join33MEOUKP4u7BRQaZ1A", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - COMMITMENTS (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsDetails", "shortName": "COMMITMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_Fk7CpAVK10uwm4jOA1BTUA", "decimals": "INF", "first": true, "lang": null, "name": "ssaau:FounderSharesAndWarrantsDemands", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_Join33MEOUKP4u7BRQaZ1A", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_Fk7CpAVK10uwm4jOA1BTUA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares_6i4NST_38UeUN04BrV1QVA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock Shares (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityPreferredStockSharesDetails", "shortName": "STOCKHOLDERS' EQUITY - Preferred Stock Shares (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R32": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_Fk7CpAVK10uwm4jOA1BTUA", "decimals": "INF", "first": true, "lang": null, "name": "ssaau:CommonStockClassBConversionToClass", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_Wa8vzHXV8k2-H9nfwyDUfA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40702 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock Shares (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityCommonStockSharesDetails", "shortName": "STOCKHOLDERS' EQUITY - Common Stock Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_Fk7CpAVK10uwm4jOA1BTUA", "decimals": "INF", "first": true, "lang": null, "name": "ssaau:CommonStockClassBConversionToClass", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_Wa8vzHXV8k2-H9nfwyDUfA", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_Fk7CpAVK10uwm4jOA1BTUA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares", "reportCount": 1, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - WARRANTS (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails", "shortName": "WARRANTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ssaau:WarrantLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_us-gaap_ClassOfWarrantOrRightAxis_ssaau_PublicWarrantsMember_YWUk-2AiVEm8kxVxkOR7fg", "decimals": null, "lang": "en-US", "name": "ssaau:WarrantsAndRightsOutstandingExercisablePeriodAfterBusinessCombination", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_Fk7CpAVK10uwm4jOA1BTUA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AssetsHeldInTrustNoncurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - FAIR VALUE MEASUREMENTS (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails", "shortName": "FAIR VALUE MEASUREMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_drZ9KKdjzESUPKO2pF_h8A", "decimals": "0", "lang": null, "name": "us-gaap:AssetsHeldInTrustNoncurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_LhRgc1vIbU6xgRgCMpFARA", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_Wa8vzHXV8k2-H9nfwyDUfA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - FAIR VALUE MEASUREMENTS - Level 3 Fair Value Measurements Inputs (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsLevel3FairValueMeasurementsInputsDetails", "shortName": "FAIR VALUE MEASUREMENTS - Level 3 Fair Value Measurements Inputs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_LhRgc1vIbU6xgRgCMpFARA", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_Wa8vzHXV8k2-H9nfwyDUfA", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_Fk7CpAVK10uwm4jOA1BTUA", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares", "reportCount": 1, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40903 - Disclosure - FAIR VALUE MEASUREMENTS - Change in the Fair Value of the Warrant Liabilities (Details)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfWarrantLiabilitiesDetails", "shortName": "FAIR VALUE MEASUREMENTS - Change in the Fair Value of the Warrant Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_BhKrqRXDjUO5wK-9tdJN3A", "decimals": "0", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_PPVafkN1t0GODQRSEJxskQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Condensed Statement of Operations", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations", "shortName": "Condensed Statement of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_4_1_2021_To_6_30_2021_PPVafkN1t0GODQRSEJxskQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_us-gaap_StatementClassOfStockAxis_ssaau_CommonClassaSubjectToRedemptionMember__XCMTzwzPkCYLMS8YpZWWQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_shares_6i4NST_38UeUN04BrV1QVA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00205 - Statement - Condensed Statement of Operations (Parenthetical)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperationsParenthetical", "shortName": "Condensed Statement of Operations (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_p_KSJXLydkSB8gLCswRcqg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Condensed Statement of Changes in Stockholders' Equity", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity", "shortName": "Condensed Statement of Changes in Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_ssaau_CommonClassaNotSubjectToRedemptionMember_bh70gjVB1EifYQmhrw9aKg", "decimals": "0", "lang": null, "name": "ssaau:UnitsIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "As_Of_6_30_2021_Fk7CpAVK10uwm4jOA1BTUA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Unit_Standard_shares_6i4NST_38UeUN04BrV1QVA", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00305 - Statement - Condensed Statement of Changes in Stockholders' Equity (Parenthetical)", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquityParenthetical", "shortName": "Condensed Statement of Changes in Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Condensed Statement of Cash Flows", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows", "shortName": "Condensed Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_q56bjQKS40edPVLA3ucX1g", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - ORGANIZATION AND PLANS OF BUSINESS OPERATIONS", "role": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperations", "shortName": "ORGANIZATION AND PLANS OF BUSINESS OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "ssaau-20210630x10q.htm", "contextRef": "Duration_1_1_2021_To_6_30_2021_3ULCf0zYZ0O-hVGtMf60cQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 32, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "label": "Scenario Unspecified [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r110", "r137", "r195" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "stringItemType" }, "ssaau_AccruedOfferingCost": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of offering costs accrued but not yet paid as of the period date.", "label": "Accrued Offering Cost", "terseLabel": "Accrued offering costs" } } }, "localname": "AccruedOfferingCost", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ssaau_AccruedOfferingCostsRelatedParty": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of offering costs accrued, related party but not yet paid as of the period date.", "label": "Accrued Offering Costs, Related Party", "terseLabel": "Accrued offering costs - related party" } } }, "localname": "AccruedOfferingCostsRelatedParty", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ssaau_AdministrativeSupportAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for Administrative Support Agreement.", "label": "Administrative Support Agreement [Member]", "terseLabel": "Administrative Support Agreement" } } }, "localname": "AdministrativeSupportAgreementMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ssaau_AggregateNumberOfSharesOwned": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares owned by the founders after the impact of the stock dividend.", "label": "Aggregate Number Of Shares Owned", "terseLabel": "Aggregate number of shares owned" } } }, "localname": "AggregateNumberOfSharesOwned", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "sharesItemType" }, "ssaau_AmountHeldInTrustAccountFromPrivatePlacementWarrantsIssuance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount held in the trust account from private placement warrants issuance proceeds.", "label": "Amount Held In The Trust Account From Private Placement Warrants Issuance", "terseLabel": "Amount held in the trust account from private placement warrants issuance proceeds" } } }, "localname": "AmountHeldInTrustAccountFromPrivatePlacementWarrantsIssuance", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_AssetsHeldInTrustAccountPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of accounting policy for assets held in trust.", "label": "Assets Held In Trust Account, Policy [Policy Text Block]", "terseLabel": "Marketable Securities Held in Trust Account" } } }, "localname": "AssetsHeldInTrustAccountPolicyPolicyTextBlock", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ssaau_ChangeInValueCommonShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity impact of the change in value of common stock or shares subject to possible redemption.", "label": "Change in value common (in shares)", "terseLabel": "Change in value of common stock subject to possible redemption (in shares)" } } }, "localname": "ChangeInValueCommonShares", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "ssaau_ChangeInValueCommonSharesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the change in value of common stock or shares subject to possible redemption.", "label": "Change in value common shares amount", "terseLabel": "Change in value of common stock subject to possible redemption" } } }, "localname": "ChangeInValueCommonSharesAmount", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "ssaau_ChangeInValueOfCommonStockSubjectToPossibleRedemption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of change in value of common stock subject to possible redemption, classified as non-cash investing and financing activity.", "label": "Change In Value Of Common Stock Subject To Possible Redemption", "terseLabel": "Change in value of common stock subject to possible redemption" } } }, "localname": "ChangeInValueOfCommonStockSubjectToPossibleRedemption", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ssaau_ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of adjustment of exercise price of warrants based on market value and newly issued price.", "label": "Class of Warrant or Right, Adjustment of Exercise Price of Warrants or Rights, Percent, Based On Market Value And Newly Issued Share Price", "terseLabel": "Adjustment of exercise price of warrants based on market value and newly issued price (as a percent)" } } }, "localname": "ClassOfWarrantOrRightAdjustmentOfExercisePriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedSharePrice", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "percentItemType" }, "ssaau_ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of adjustment of redemption price of stock based on market value and newly issued price.", "label": "Class of Warrant or Right, Adjustment of Redemption Price of Warrants or Rights, Percent, Based On Market Value And Newly Issued Price 1", "terseLabel": "Adjustment of redemption price of stock based on market value and newly issued price (as a percent)" } } }, "localname": "ClassOfWarrantOrRightAdjustmentOfRedemptionPriceOfWarrantsOrRightsPercentBasedOnMarketValueAndNewlyIssuedPrice1", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "percentItemType" }, "ssaau_ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum threshold period during which a written notice is required for redemption of warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Class Of Warrant Or Right, Minimum Threshold Written Notice Period For Redemption Of Warrants", "terseLabel": "Minimum threshold written notice period for redemption of public warrants" } } }, "localname": "ClassOfWarrantOrRightMinimumThresholdWrittenNoticePeriodForRedemptionOfWarrants", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "durationItemType" }, "ssaau_ClassOfWarrantOrRightPriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Price of Warrants or Rights", "terseLabel": "Price of warrant", "verboseLabel": "Price of warrants" } } }, "localname": "ClassOfWarrantOrRightPriceOfWarrantsOrRights", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "ssaau_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of the entity's common stock which would be required to be attained to trigger the redemption of warrants.", "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Right, Stock Price Trigger", "terseLabel": "Stock price trigger for redemption of public warrants (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightStockPriceTrigger", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "perShareItemType" }, "ssaau_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified consecutive trading days for stock price trigger considered for redemption of warrants.", "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Consecutive Trading Days", "terseLabel": "Threshold consecutive trading days for redemption of public warrants" } } }, "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "integerItemType" }, "ssaau_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days for stock price trigger considered for redemption of warrants.", "label": "Class Of Warrant Or Right, Redemption Of Warrants Or Rights, , Threshold Trading Days", "terseLabel": "Threshold trading days for redemption of public warrants" } } }, "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "integerItemType" }, "ssaau_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right, Redemption Price Of Warrants Or Rights", "terseLabel": "Redemption price per warrant (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "perShareItemType" }, "ssaau_CommonClassaNotSubjectToRedemptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation that is not subject to redemption.", "label": "Common Classa Not Subject To Redemption [Member]", "terseLabel": "Class A Common Stock Not Subject to Redemption" } } }, "localname": "CommonClassaNotSubjectToRedemptionMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestatementOfPreviouslyIssuedFinancialStatementAsOfJanuary282021Details", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "ssaau_CommonClassaSubjectToRedemptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation that is subject to redemption.", "label": "Common Classa Subject To Redemption [Member]", "terseLabel": "Class A Common Stock Subject to Redemption" } } }, "localname": "CommonClassaSubjectToRedemptionMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestatementOfPreviouslyIssuedFinancialStatementAsOfJanuary282021Details", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperationsParenthetical" ], "xbrltype": "domainItemType" }, "ssaau_CommonStockClassBConversionToClass": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of Common Stock Class B into Common Stock Class A.", "label": "Common Stock Class B Conversion to Class A", "terseLabel": "Class B common stock conversion ratio to Class B" } } }, "localname": "CommonStockClassBConversionToClass", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityCommonStockSharesDetails" ], "xbrltype": "pureItemType" }, "ssaau_CommonStockNumberOfVotesPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of votes that each common share is entitled.", "label": "Common Stock, Number Of Votes Per Share", "terseLabel": "Common shares, votes per share" } } }, "localname": "CommonStockNumberOfVotesPerShare", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityCommonStockSharesDetails" ], "xbrltype": "integerItemType" }, "ssaau_CommonStockSubjectToPossibleRedemptionShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of the shares of common stock subject to possible redemption.", "label": "Common Stock Subject To Possible Redemption, Shares", "negatedLabel": "Common stock subject to possible redemption (in shares)" } } }, "localname": "CommonStockSubjectToPossibleRedemptionShares", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "ssaau_CommonStockSubjectToPossibleRedemptionValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of common stock subject to possible redemption.", "label": "Common Stock Subject To Possible Redemption, Value", "negatedLabel": "Common stock subject to possible redemption" } } }, "localname": "CommonStockSubjectToPossibleRedemptionValue", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "ssaau_ConditionForFutureBusinessCombinationThresholdNetTangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The threshold net tangible assets which the reporting entity must maintain in order to proceed with a business combination utilizing the proceeds of the offering.", "label": "Condition for future business combination threshold Net Tangible Assets" } } }, "localname": "ConditionForFutureBusinessCombinationThresholdNetTangibleAssets", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_ConvertibleStockConversionRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The ratio to be applied to the stock in a conversion of convertible stock.", "label": "Convertible Stock Conversion Ratio", "terseLabel": "Ratio to be applied to the stock in the conversion" } } }, "localname": "ConvertibleStockConversionRatio", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityCommonStockSharesDetails" ], "xbrltype": "pureItemType" }, "ssaau_DeferredFeePerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the deferred fee per unit.", "label": "Deferred Fee Per Unit", "terseLabel": "Deferred fee per unit" } } }, "localname": "DeferredFeePerUnit", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsDetails" ], "xbrltype": "perShareItemType" }, "ssaau_DeferredOfferingCostsIncludedInAccruedOfferingCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of deferred offering costs included in accrued offering cost.", "label": "Deferred Offering Costs Included In Accrued Offering Cost", "terseLabel": "Deferred offering cost included in accrued offering cost" } } }, "localname": "DeferredOfferingCostsIncludedInAccruedOfferingCost", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ssaau_DeferredOfferingCostsNoncurrent": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails": { "order": 2.0, "parentTag": "ssaau_TransactionCosts", "weight": 1.0 }, "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of balance sheet date of underwriting fees payable or deferred, classified as noncurrent.", "label": "Deferred Offering Costs Noncurrent", "terseLabel": "Deferred underwriting fee payable" } } }, "localname": "DeferredOfferingCostsNoncurrent", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "ssaau_DenominatorForCalculationOfEarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Denominator For Calculation Of Earnings Per Share [Abstract]", "terseLabel": "Denominator: Weighted average Class A Common Stock subject to possible redemption" } } }, "localname": "DenominatorForCalculationOfEarningsPerShareAbstract", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails" ], "xbrltype": "stringItemType" }, "ssaau_EmergingGrowthCompanyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the accounting policy on Emerging Growth Company.", "label": "Emerging Growth Company [Policy Text Block]", "terseLabel": "Emerging Growth Company" } } }, "localname": "EmergingGrowthCompanyPolicyTextBlock", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ssaau_FounderSharesAndWarrantsDemands": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum number of demands the Founder Shares, Private Placement Warrants and any warrants that may be issued on conversion of Working Capital Loans (and any Class A common stock issuable upon the exercise of the Private Placement Warrants or warrants issued upon conversion of the Working Capital Loans and upon conversion of the Founder Shares) are entitled to.", "label": "Founder Shares and Warrants Demands", "terseLabel": "Number of demands securities are entitled to" } } }, "localname": "FounderSharesAndWarrantsDemands", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsDetails" ], "xbrltype": "integerItemType" }, "ssaau_FounderSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to founder shares.", "label": "Founder Shares [Member]", "terseLabel": "Founder Shares" } } }, "localname": "FounderSharesMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "domainItemType" }, "ssaau_InitialClassificationOfCommonStockSubjectToPossibleRedemption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of initial classification of common stock subject to possible redemption, classified as non-cash investing and financing activity.", "label": "Initial Classification Of Common Stock Subject To Possible Redemption", "terseLabel": "Initial classification of common stock subject to redemption" } } }, "localname": "InitialClassificationOfCommonStockSubjectToPossibleRedemption", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ssaau_InitialFairValueOfWarrantLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The initial fair value classification of warrant liabilities disclosed in the supplemental non-cash cash flow activities.", "label": "Initial Fair Value Of Warrant Liabilities", "verboseLabel": "Initial fair value of warrant liability" } } }, "localname": "InitialFairValueOfWarrantLiabilities", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ssaau_InitialPublicOfferingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "INITIAL PUBLIC OFFERING" } } }, "localname": "InitialPublicOfferingAbstract", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "xbrltype": "stringItemType" }, "ssaau_InitialPublicOfferingTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on information about initial public offering.", "label": "Initial Public Offering [Text Block]", "terseLabel": "INITIAL PUBLIC OFFERING" } } }, "localname": "InitialPublicOfferingTextBlock", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOffering" ], "xbrltype": "textBlockItemType" }, "ssaau_MaximumBorrowingCapacityOfRelatedPartyPromissoryNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of maximum borrowing capacity of related party promissory note.", "label": "Maximum Borrowing Capacity of Related Party Promissory Note", "terseLabel": "Maximum borrowing capacity of related party promissory note" } } }, "localname": "MaximumBorrowingCapacityOfRelatedPartyPromissoryNote", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_MaximumInterestToPayDissolutionExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of maximum interest to pay dissolution expenses.", "label": "Maximum Interest To Pay Dissolution Expenses", "terseLabel": "Maximum interest to pay dissolution expenses" } } }, "localname": "MaximumInterestToPayDissolutionExpenses", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_MaximumLoansConvertibleIntoWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The maximum amount which a potential loan could have repaid through issuance of warrants.", "label": "maximum Loans Convertible Into Warrants", "terseLabel": "Loan conversion agreement warrant" } } }, "localname": "MaximumLoansConvertibleIntoWarrants", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of time after completion of a business combination in which the reporting entity is required to file a registration statement with the SEC.", "label": "Maximum Period After Business Combination In Which To File Registration Statement", "terseLabel": "Maximum period after business combination in which to file registration statement" } } }, "localname": "MaximumPeriodAfterBusinessCombinationInWhichToFileRegistrationStatement", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "durationItemType" }, "ssaau_Maximumborrowingcapacityofrelatedpartypromissorynote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of maximum borrowing capacity of related party promissory note.", "label": "MaximumBorrowingCapacityOfRelatedPartyPromissoryNote" } } }, "localname": "Maximumborrowingcapacityofrelatedpartypromissorynote", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_MeasurementInputNumberOfTrialsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input using number of trials.", "label": "Measurement Input Number Of Trials [Member]", "terseLabel": "Trials" } } }, "localname": "MeasurementInputNumberOfTrialsMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsLevel3FairValueMeasurementsInputsDetails" ], "xbrltype": "domainItemType" }, "ssaau_NetProceedsFromInitialPublicOffering": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public, net of underwriting discounts paid.", "label": "Net Proceeds From Initial Public Offering", "terseLabel": "Proceeds from sale of Units, net of underwriting discounts paid" } } }, "localname": "NetProceedsFromInitialPublicOffering", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ssaau_NonRedeemableClassCommonStockAndClassBCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Non Redeemable Class A Common Stock And Class B Common Stock.", "label": "Non Redeemable Class Common Stock And Class B Common Stock [Member]", "terseLabel": "Non redeemable Class A and Class B Common Stock" } } }, "localname": "NonRedeemableClassCommonStockAndClassBCommonStockMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations" ], "xbrltype": "domainItemType" }, "ssaau_NumberOfDaysToRedeemSharesIfBusinessCombinationIsNotCompletedBySpecifiedDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of days to redeem shares if business combination is not completed by specified date.", "label": "Number Of Days To Redeem Shares If Business Combination Is Not Completed By Specified Date", "terseLabel": "Number of days to redeem shares if business combination is not completed by specified date" } } }, "localname": "NumberOfDaysToRedeemSharesIfBusinessCombinationIsNotCompletedBySpecifiedDate", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "durationItemType" }, "ssaau_NumberOfSharesIssuedPerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of shares in a unit.", "label": "Number of Shares Issued Per Unit", "terseLabel": "Number of shares in a unit" } } }, "localname": "NumberOfSharesIssuedPerUnit", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "ssaau_NumberOfWarrantsIssuedPerUnit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of warrants in a unit.", "label": "Number of Warrants Issued Per Unit", "terseLabel": "Number of warrants in a unit" } } }, "localname": "NumberOfWarrantsIssuedPerUnit", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "ssaau_NumeratorForCalculationOfEarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Numerator For Calculation Of Earnings Per Share [Abstract]", "terseLabel": "Numerator: Earnings attributable to Class A Common Stock subject to possible redemption" } } }, "localname": "NumeratorForCalculationOfEarningsPerShareAbstract", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails" ], "xbrltype": "stringItemType" }, "ssaau_NumeratorNetLossMinusNetEarningsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Numerator: Net Loss Minus Net Earnings Abstract", "terseLabel": "Numerator: Net loss minus net earnings" } } }, "localname": "NumeratorNetLossMinusNetEarningsAbstract", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails" ], "xbrltype": "stringItemType" }, "ssaau_OfferingCostOfStockIssuanceInInitialPublicOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of stock offering cost in initial public offering.", "label": "Offering Cost Of Stock Issuance In Initial Public Offering", "terseLabel": "Offering costs charged to shareholders' equity" } } }, "localname": "OfferingCostOfStockIssuanceInInitialPublicOffering", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_OfferingCostsAllocatedToWarrantLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of offering costs allocated to warrant liability.", "label": "Offering Costs Allocated To Warrant Liability", "terseLabel": "Offering costs related to warrant liabilities" } } }, "localname": "OfferingCostsAllocatedToWarrantLiability", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_OfferingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the accounting policy on offering costs.", "label": "Offering Costs Policy [Text Block]", "terseLabel": "Offering Costs" } } }, "localname": "OfferingCostsPolicyTextBlock", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ssaau_PaymentsForInvestmentOfCashInTrustAccount": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow for investment of cash in trust account.", "label": "Payments for investment of cash in Trust Account", "negatedLabel": "Investment of cash in Trust Account" } } }, "localname": "PaymentsForInvestmentOfCashInTrustAccount", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ssaau_PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of shares which the reporting entity is obligated to redeem if a business combination is not consummated using the offering proceeds within a specified period.", "label": "Percentage Obligation To Redeem Public Shares If Entity Does Not Complete A Business Combination", "terseLabel": "Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent)" } } }, "localname": "PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "percentItemType" }, "ssaau_PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The ratio of gross proceeds from a future offering to total equity proceeds which is used to measure whether dilution of the warrant has occurred. If aggregate gross proceeds from a new offering exceeds a specified percentage of total equity proceeds, the warrant exercise price will be adjusted.", "label": "Percentage Of Gross New Proceeds To Total Equity Proceeds Used To Measure Dilution Of Warrant", "terseLabel": "Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant" } } }, "localname": "PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "percentItemType" }, "ssaau_PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of time after filing within which the registration statement filed with the SEC is expected to become effective.", "label": "Period Of Time Within Which Registration Statement Is Expected To Become Effective", "terseLabel": "Period of time within which registration statement is expected to become effective" } } }, "localname": "PeriodOfTimeWithinWhichRegistrationStatementIsExpectedToBecomeEffective", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "durationItemType" }, "ssaau_PrivatePlacementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "PRIVATE PLACEMENT" } } }, "localname": "PrivatePlacementAbstract", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "xbrltype": "stringItemType" }, "ssaau_PrivatePlacementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on information about private placement.", "label": "Private Placement [Text Block]", "terseLabel": "PRIVATE PLACEMENT" } } }, "localname": "PrivatePlacementTextBlock", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacement" ], "xbrltype": "textBlockItemType" }, "ssaau_PrivatePlacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a redeemable warrant (Private Placement Warrant) that entitles the holder to purchase shares of common stock if the underwriter's option is exercised in full.", "label": "Private Placement Warrants [Member]", "terseLabel": "Private Placement Warrants" } } }, "localname": "PrivatePlacementWarrantsMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "ssaau_PromissoryNoteWithRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for promissory note with related party.", "label": "Promissory Note With Related Party [Member]", "terseLabel": "Promissory Note with Related Party" } } }, "localname": "PromissoryNoteWithRelatedPartyMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ssaau_PublicAndPrivatePlacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a redeemable warrant (Public and Private Placement Warrant) that entitles the holder to purchase shares of common stock if the underwriter's option is exercised in full.", "label": "Public And Private Placement Warrants [Member]", "terseLabel": "Public And Private Placement Warrants [Member]" } } }, "localname": "PublicAndPrivatePlacementWarrantsMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "ssaau_PublicWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a redeemable warrant (Public Warrant) that entitles the holder to purchase shares of common stock subject to adjustment.", "label": "Public Warrants [Member]", "terseLabel": "Public Warrants" } } }, "localname": "PublicWarrantsMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "ssaau_RedemptionOfSharesCalculatedBasedOnNumberOfBusinessDaysPriorToConsummationOfBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the redemption of shares calculated based on number of business days prior to consummation of business combination.", "label": "Redemption of Shares Calculated Based On Number Of Business Days Prior To Consummation Of Business Combination", "terseLabel": "Redemption of shares calculated based on business days prior to consummation of business combination (in days)" } } }, "localname": "RedemptionOfSharesCalculatedBasedOnNumberOfBusinessDaysPriorToConsummationOfBusinessCombination", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "integerItemType" }, "ssaau_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the scenario, where redemption of warrants when the price per share of class a common stock equals or exceeds $10.00.", "label": "Redemption Of Warrants When Price Per Share Of Class Common Stock Equals Or Exceeds10.00 [Member]", "terseLabel": "Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $10.00" } } }, "localname": "RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds10.00Member", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "ssaau_RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for the scenario, where redemption of warrants when the price per share of class a common stock equals or exceeds $18.00.", "label": "Redemption Of Warrants When Price Per Share Of Class Common Stock Equals Or Exceeds18.00 [Member]", "terseLabel": "Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00" } } }, "localname": "RedemptionOfWarrantsWhenPricePerShareOfClassCommonStockEqualsOrExceeds18.00Member", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "ssaau_RelatedPartyLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for related party loans.", "label": "Related Party Loans [Member]", "terseLabel": "Related Party Loans" } } }, "localname": "RelatedPartyLoansMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ssaau_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The contractual monthly amount to be paid for support services.", "label": "Related Party Transaction, Expenses from Transactions with Related Party Per Month", "terseLabel": "Expenses per month" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPerMonth", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of time after completion of a business combination during which the shares or warrant may not be transferred.", "label": "Restrictions On Transfer Period Of Time After Business Combination Completion", "terseLabel": "Restrictions on transfer period of time after business combination completion" } } }, "localname": "RestrictionsOnTransferPeriodOfTimeAfterBusinessCombinationCompletion", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "durationItemType" }, "ssaau_SaleOfStockOtherOfferingCosts": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails": { "order": 3.0, "parentTag": "ssaau_TransactionCosts", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of other offering costs incurred.", "label": "Sale of Stock, Other Offering Costs", "terseLabel": "Other offering costs" } } }, "localname": "SaleOfStockOtherOfferingCosts", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_SaleOfStockUnderwritingFees": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails": { "order": 1.0, "parentTag": "ssaau_TransactionCosts", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of offering fees incurred and paid for underwriters.", "label": "Sale of Stock, Underwriting fees", "terseLabel": "Underwriting fees" } } }, "localname": "SaleOfStockUnderwritingFees", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_SponsorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for sponsor.", "label": "Sponsor [Member]", "terseLabel": "Sponsor" } } }, "localname": "SponsorMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "domainItemType" }, "ssaau_TemporaryEquityPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of accounting policy for temporary equity.", "label": "Temporary Equity, Policy [Policy Text Block]", "terseLabel": "Class A Common Stock Subject to Possible Redemption" } } }, "localname": "TemporaryEquityPolicyPolicyTextBlock", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ssaau_ThresholdIssuePriceForCapitalRaisingPurposesInConnectionWithClosingOfBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to threshold issue price for capital raising purposes in connection with the closure of a business combination.", "label": "Threshold Issue Price for Capital Raising Purposes in Connection with the Closing of a Business Combination", "terseLabel": "Threshold issue price per share" } } }, "localname": "ThresholdIssuePriceForCapitalRaisingPurposesInConnectionWithClosingOfBusinessCombination", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "perShareItemType" }, "ssaau_ThresholdMinimumAggregateFairMarketValueAsPercentageOfNetAssetsHeldIntrustAccount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the threshold minimum aggregate fair market value as a percentage of the net assets held in the Trust Account.", "label": "Threshold Minimum Aggregate Fair Market Value As Percentage Of Net Assets Held Intrust Account", "terseLabel": "Threshold minimum aggregate fair market value as a percentage of the net assets held in the Trust Account" } } }, "localname": "ThresholdMinimumAggregateFairMarketValueAsPercentageOfNetAssetsHeldIntrustAccount", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "percentItemType" }, "ssaau_ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of time after a business combination which must elapse before consideration of the share price condition for transfer of shares.", "label": "Threshold Period After Business Combination In Which Specified Trading Days Within Any Specified Trading Day Period Commences", "terseLabel": "Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences" } } }, "localname": "ThresholdPeriodAfterBusinessCombinationInWhichSpecifiedTradingDaysWithinAnySpecifiedTradingDayPeriodCommences", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "durationItemType" }, "ssaau_TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of trading days after a business combination during which the share price is compared to the specified dilution trigger share price in order to determine whether the warrant exercise price should be adjusted.", "label": "Trading Period After Business Combination Used To Measure Dilution of Warrant", "terseLabel": "Trading period after business combination used to measure dilution of warrant" } } }, "localname": "TradingPeriodAfterBusinessCombinationUsedToMeasureDilutionOfWarrant", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "integerItemType" }, "ssaau_TransactionCosts": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of transaction costs incurred.", "label": "Transaction Costs", "totalLabel": "Transaction Costs" } } }, "localname": "TransactionCosts", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The share price threshold that must be achieved in order to waive the restriction on transfer of shares during a restricted period after a business combination.", "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Stock Price Trigger", "terseLabel": "Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share)" } } }, "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationStockPriceTrigger", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "perShareItemType" }, "ssaau_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "When determining the condition for transfer of shares without restriction after a business combination, the number of consecutive trading days used to observe the share price.", "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Consecutive Trading Days", "terseLabel": "Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination" } } }, "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdConsecutiveTradingDays", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "integerItemType" }, "ssaau_TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "When determining the condition for transfer of shares without restriction after a business combination, the number of days in which the share price must exceed the specified amount.", "label": "Transfer, Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination, Threshold Trading Days", "terseLabel": "Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination" } } }, "localname": "TransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombinationThresholdTradingDays", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "integerItemType" }, "ssaau_UnitEachConsistingOfOneClassCommonStockAndOneThirdRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Unit each consisting of one class common stock .", "label": "Unit Each Consisting Of One Class Common Stock And One Third Redeemable Warrant [Member]", "terseLabel": "Unit Each Consisting Of One Class Common Stock And One Third of one Redeemable Warrant" } } }, "localname": "UnitEachConsistingOfOneClassCommonStockAndOneThirdRedeemableWarrantMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "ssaau_UnitsIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new units issued during the period.", "label": "Units Issued During Period, Shares, New Issues", "terseLabel": "Sale of 31,050,000 Units, net of underwriting discount and offering expenses (in shares)", "verboseLabel": "Number of units sold" } } }, "localname": "UnitsIssuedDuringPeriodSharesNewIssues", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "sharesItemType" }, "ssaau_UnitsIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new unit issued during the period.", "label": "Units Issued During Period, Value, New Issues", "terseLabel": "Sale of 31,050,000 Units, net of underwriting discount and offering expenses" } } }, "localname": "UnitsIssuedDuringPeriodValueNewIssues", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "ssaau_UnrealizedGainLossOnInvestment": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_TemporaryEquityNetIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain Loss On Investment", "verboseLabel": "Unrealized gain on marketable securities held in Trust Account" } } }, "localname": "UnrealizedGainLossOnInvestment", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "ssaau_WarrantInstrumentsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for Warrant Instruments.", "label": "Warrant Instruments, Policy [Policy Text Block]", "verboseLabel": "Warrants Exercisable for Class A Common Stock" } } }, "localname": "WarrantInstrumentsPolicyPolicyTextBlock", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ssaau_WarrantLiabilitiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Warrant Liabilities Disclosure [Text Block]", "terseLabel": "WARRANTS" } } }, "localname": "WarrantLiabilitiesDisclosureTextBlock", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrants" ], "xbrltype": "textBlockItemType" }, "ssaau_WarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "WARRANTS" } } }, "localname": "WarrantsAbstract", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "xbrltype": "stringItemType" }, "ssaau_WarrantsAndRightsOutstandingExercisablePeriodAfterBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The warrants exercisable term after the completion of a business combination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Warrants And Rights Outstanding, Exercisable Period After Business Combination", "terseLabel": "Public Warrants exercisable term after the completion of a business combination" } } }, "localname": "WarrantsAndRightsOutstandingExercisablePeriodAfterBusinessCombination", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "durationItemType" }, "ssaau_WarrantsAndRightsOutstandingExercisablePeriodFromClosingOfInitialPublicOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The warrants exercisable term from the closing of the initial public offering, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Warrants And Rights Outstanding, Exercisable Period From Closing Of Initial Public Offering", "terseLabel": "Public Warrants exercisable term from the closing of the initial public offering" } } }, "localname": "WarrantsAndRightsOutstandingExercisablePeriodFromClosingOfInitialPublicOffering", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "durationItemType" }, "ssaau_WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price.", "label": "Warrants Each Whole Warrant Exercisable For One Share Of Class Common Stock At Exercise Price [Member]", "terseLabel": "Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50" } } }, "localname": "WarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "ssaau_WorkingCapitalLoansWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Working capital loans warrant.", "label": "Working Capital Loans Warrant [Member]", "terseLabel": "Working capital loans warrant" } } }, "localname": "WorkingCapitalLoansWarrantMember", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ssaau_Workingcapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of working capital.", "label": "WorkingCapital" } } }, "localname": "Workingcapital", "nsuri": "http://www.ScienceStrategicAcquisitionCorpAlpha.com/20210630", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restatement of Previously Issued Financial Statement as of January 28, 2021" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r11", "r142" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "verboseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestatementOfPreviouslyIssuedFinancialStatementAsOfJanuary282021Details", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r52", "r53", "r55", "r139", "r140", "r141" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r112", "r118", "r125" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Sale of 5,473,333 private placement warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r48", "r93", "r95", "r99", "r102", "r155", "r159", "r178", "r214", "r221" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r5", "r24", "r48", "r102", "r155", "r159", "r178" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldInTrustNoncurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.", "label": "Marketable securities held in Trust Account", "verboseLabel": "Marketable securities held in Trust Account" } } }, "localname": "AssetsHeldInTrustNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [TEXT BLOCK]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r16", "r42" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash held outside the Trust Account", "terseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r6", "r43", "r45" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r37", "r42", "r44" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash - End of period", "periodStartLabel": "Cash - Beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r37", "r179" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net Change in Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "terseLabel": "Federal Depository Insurance Coverage" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Disclosure of Non-Cash Investing and Financing Activities:", "terseLabel": "Non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r46", "r48", "r68", "r69", "r70", "r73", "r75", "r80", "r81", "r82", "r102", "r178" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestatementOfPreviouslyIssuedFinancialStatementAsOfJanuary282021Details", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquityParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperationsParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityCommonStockSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r126", "r138" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class Of Warrant Or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrants", "verboseLabel": "Exercise price of warrant" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of shares issuable per warrant", "verboseLabel": "Number of shares per warrant" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Sale of Private Placement Warrants (in shares)", "verboseLabel": "Number of warrants to purchase shares issued" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r126", "r138" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r20", "r109", "r216", "r224" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMMITMENTS" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r106", "r107", "r108", "r111" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Class A Common Stock" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestatementOfPreviouslyIssuedFinancialStatementAsOfJanuary282021Details", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquityParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.", "label": "Common Class B [Member]", "terseLabel": "Class B Common Stock" } } }, "localname": "CommonClassBMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsShares": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.", "label": "Common Stock Dividends, Shares", "terseLabel": "Share dividend" } } }, "localname": "CommonStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common shares, par value, (per share)", "verboseLabel": "Common shares, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common shares, shares authorized", "verboseLabel": "Common shares, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common shares, shares issued", "verboseLabel": "Common shares, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r10", "r118" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common shares, shares outstanding", "verboseLabel": "Common shares, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r10" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestatementOfPreviouslyIssuedFinancialStatementAsOfJanuary282021Details", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r86", "r220" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r30" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "terseLabel": "Operating costs" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCurrent": { "auth_ref": [ "r23" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.", "label": "Deferred Costs, Current", "verboseLabel": "Deferred offering costs" } } }, "localname": "DeferredCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Derivative Liability, Measurement Input" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsLevel3FairValueMeasurementsInputsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic and diluted net loss per share" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r45", "r76", "r77" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r52", "r53", "r55", "r57", "r63", "r65", "r79", "r103", "r118", "r125", "r139", "r140", "r141", "r152", "r153", "r180", "r181", "r182", "r183", "r184", "r185", "r227", "r228", "r229" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]" } } }, "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestatementOfPreviouslyIssuedFinancialStatementAsOfJanuary282021Details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r40", "r113" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of warrant liability", "verboseLabel": "Change in fair value of warrant liabilities" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsLevel3FairValueMeasurementsInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r163", "r164", "r165", "r174" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsLevel3FairValueMeasurementsInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of quantitative information regarding Level 3 fair value measurements inputs" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r163", "r164" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Company's assets that are measured at fair value on a recurring basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r136", "r164", "r197", "r198", "r199" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfWarrantLiabilitiesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r163", "r164", "r167", "r168", "r175" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r128", "r129", "r134", "r136", "r164", "r197" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r136", "r164", "r199" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfWarrantLiabilitiesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfWarrantLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfWarrantLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r169", "r174" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfWarrantLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r169", "r174" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of change in the fair value of the warrant liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "auth_ref": [ "r172" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3", "terseLabel": "Transfers into Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfWarrantLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3", "terseLabel": "Transfers out of Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfWarrantLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r170" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "verboseLabel": "Change in fair value of warrant liability" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfWarrantLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r171" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "terseLabel": "Initial fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfWarrantLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r169" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Fair Value at June 30, 2021", "periodStartLabel": "Balance December 31, 2020" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfWarrantLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r136", "r197", "r198", "r199" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfWarrantLiabilitiesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r173", "r175" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r45", "r176", "r177" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "I P O [Member]", "terseLabel": "Initial Public Offering" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r28", "r93", "r94", "r97", "r98", "r100", "r213", "r217", "r219", "r226" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statement of Operations" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r27", "r45", "r144", "r145", "r148", "r149", "r150", "r151", "r232" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r39" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r39" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r17", "r48", "r96", "r102", "r156", "r159", "r160", "r178" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "terseLabel": "Total Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestatementOfPreviouslyIssuedFinancialStatementAsOfJanuary282021Details", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r15", "r48", "r102", "r178", "r215", "r223" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r19", "r48", "r102", "r156", "r159", "r160", "r178" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input Exercise Price [Member]", "terseLabel": "Exercise price" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsLevel3FairValueMeasurementsInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input Expected Term [Member]", "terseLabel": "Term (years)" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsLevel3FairValueMeasurementsInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input Price Volatility [Member]", "terseLabel": "Expected volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsLevel3FairValueMeasurementsInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input Risk Free Interest Rate [Member]", "terseLabel": "Weighted average risk-free interest rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsLevel3FairValueMeasurementsInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input Share Price [Member]", "terseLabel": "Stock price on valuation date" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsLevel3FairValueMeasurementsInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsLevel3FairValueMeasurementsInputsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsLevel3FairValueMeasurementsInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r83", "r92" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS [TEXT BLOCK]", "terseLabel": "ORGANIZATION AND PLANS OF BUSINESS OPERATIONS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r37" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r37" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r37", "r38", "r41" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Operating Activities:", "terseLabel": "Cash Flows used in Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r25", "r26", "r29", "r41", "r48", "r56", "r58", "r59", "r60", "r61", "r64", "r65", "r71", "r93", "r94", "r97", "r98", "r100", "r102", "r178", "r218", "r225" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net Loss", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r58", "r59", "r60", "r61", "r66", "r67", "r72", "r75", "r93", "r94", "r97", "r98", "r100" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "verboseLabel": "Non-redeemable net loss" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r31" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Other income (loss), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income:", "terseLabel": "Other income (loss):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r93", "r94", "r97", "r98", "r100" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ORGANIZATION AND PLANS OF BUSINESS OPERATIONS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over Allotment Option [Member]", "terseLabel": "Over-allotment option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r35" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of offering costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value, (per share)", "verboseLabel": "Preferred stock, par value, (per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityPreferredStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Preferred shares, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityPreferredStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "verboseLabel": "Preferred shares, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityPreferredStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "verboseLabel": "Preferred shares, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityPreferredStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r9" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value; 1,000,000 authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r2", "r4", "r104", "r105" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r32" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from issuance initial public offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r32" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from the sale of Private Placements Warrants", "verboseLabel": "Aggregate purchase price" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r33" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from Related Party Debt", "terseLabel": "Proceeds from promissory note - related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r0", "r25", "r26", "r36", "r48", "r56", "r64", "r65", "r93", "r94", "r97", "r98", "r100", "r102", "r154", "r157", "r158", "r161", "r162", "r178", "r219" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net loss", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r135", "r188", "r189" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r135", "r188", "r189", "r191" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r135", "r188", "r191", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r186", "r187", "r189", "r192", "r193" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r34" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of Related Party Debt", "negatedLabel": "Repayment of promissory note - related party", "terseLabel": "Repayment of promissory note - related party" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r12", "r125", "r142", "r222", "r230", "r231" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "netLabel": "Accumulated Deficit", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestatementOfPreviouslyIssuedFinancialStatementAsOfJanuary282021Details", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r52", "r53", "r55", "r57", "r63", "r65", "r103", "r139", "r140", "r141", "r152", "r153", "r227", "r229" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted income per common share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "auth_ref": [ "r54", "r58", "r59", "r62", "r63", "r64", "r65", "r78" ], "lang": { "en-us": { "role": { "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.", "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestatementOfPreviouslyIssuedFinancialStatementAsOfJanuary282021Details" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r49", "r190", "r191" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r21", "r46", "r80", "r81", "r115", "r116", "r117", "r119", "r120", "r121", "r122", "r123", "r124", "r125" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityCommonStockSharesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance at the end (in shares)", "periodStartLabel": "Balance at the beginning (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Issue price per unit" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares": { "auth_ref": [ "r114" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of shares that would be issued, determined under the conditions specified in the contract if the settlement were to occur at the reporting date.", "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Fair Value of Shares", "netLabel": "Warrant Liability", "terseLabel": "Warrant liability", "verboseLabel": "Fair value of warrant liabilities" } } }, "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfWarrantLiabilitiesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureFairValueMeasurementsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestatementOfPreviouslyIssuedFinancialStatementAsOfJanuary282021Details", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r8", "r9", "r10", "r46", "r48", "r68", "r69", "r70", "r73", "r75", "r80", "r81", "r82", "r102", "r118", "r178" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestatementOfPreviouslyIssuedFinancialStatementAsOfJanuary282021Details", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DocumentDocumentAndEntityInformation", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquityParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperationsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r22", "r52", "r53", "r55", "r57", "r63", "r65", "r79", "r103", "r118", "r125", "r139", "r140", "r141", "r152", "r153", "r180", "r181", "r182", "r183", "r184", "r185", "r227", "r228", "r229" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquityParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperationsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statement of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Balance Sheets", "terseLabel": "Balance sheet as of January 28, 2021 (audited)" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestatementOfPreviouslyIssuedFinancialStatementAsOfJanuary282021Details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statement of Changes in Stockholders' Equity" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r52", "r53", "r55", "r79", "r200" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquityParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperationsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r9", "r10", "r118", "r125" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r9", "r10", "r118", "r125" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Aggregate purchase price" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureRelatedPartyTransactionsFounderSharesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r10", "r13", "r14", "r48", "r101", "r102", "r178" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "totalLabel": "Total Stockholders' Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r47", "r125", "r127" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r194", "r196" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureCommitmentsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureInitialPublicOfferingDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosurePrivatePlacementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "netLabel": "Common Stock Subject to Possible Redemption", "terseLabel": "Class A common stock subject to redemption", "verboseLabel": "Class A Common stock subject to possible redemption, 28,240,098 and no shares at redemption value as of June 30, 2021 and December 31, 2020, respectively" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestatementOfPreviouslyIssuedFinancialStatementAsOfJanuary282021Details", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityNetIncome": { "auth_ref": [], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of net income or loss attributable to temporary equity interest.", "label": "Temporary Equity, Net Income", "totalLabel": "Net earnings attributable to Class A Common Stock subject to possible redemption", "verboseLabel": "Less: Net earnings attributable to Class A Common Stock subject to possible redemption" } } }, "localname": "TemporaryEquityNetIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary equity, shares issued", "terseLabel": "Class A common stock subject to possible redemption, issued (in shares)" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary equity, shares outstanding", "terseLabel": "Class A common stock subject to possible redemption, outstanding (in shares)", "verboseLabel": "Number of shares subject to redemption" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureStockholdersEquityCommonStockSharesDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestatementOfPreviouslyIssuedFinancialStatementAsOfJanuary282021Details", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperationsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r40" ], "calculation": { "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "negatedTerseLabel": "Unrealized gain on marketable securities held in Trust Account", "verboseLabel": "Unrealized gain on marketable securities held in Trust Account" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfCashFlows", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r143", "r147" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r146" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits accrued for interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r84", "r85", "r87", "r88", "r89", "r90", "r91" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureOrganizationAndPlansOfBusinessOperationsDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Public Warrants expiration term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureWarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted average shares outstanding, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfNetIncomePerCommonShareDetails", "http://www.ScienceStrategicAcquisitionCorpAlpha.com/role/StatementCondensedStatementOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r193": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r233": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r234": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r235": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r236": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r237": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r238": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r239": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(b))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r51": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e22044-107793" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" } }, "version": "2.1" } ZIP 55 0001104659-21-105299-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-105299-xbrl.zip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end

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